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ABSTRACT 
Miao Chen: Towards de novo synthesis of structure-defined oligosaccharides with 
heparan sulfate biosynthetic enzymes (Under the direction of Jian Liu, Ph.D.) 
 
 
Heparan sulfate (HS), a highly sulfated polysaccharide, plays fundamental roles in a 
wide range of physiological and pathophysiological processes.  The specific structure of 
HS determines its biological function.  Various HS biosynthetic enzymes dictate the final 
structure of HS products.  As an attractive target for medical and pharmaceutical research, 
synthesis of structurally defined HS oligosaccharides is one of the major challenges in the 
field of glycobiology.  Enzymatic synthesis of HS represents a valuable complementary 
approach to chemical synthesis.  The access to the unsulfated, unepimerized HS 
backbones is an essential step towards enzymatic synthesis of HS.  In this research, we 
developed a chemoenzymatic approach for de novo synthesis of HS backbones with two 
bacterial glycosyltransferase, KfiA and PmHS2.  KfiA is an N-
acetylglucosaminyltransferase in Escherichia coli strain K5, while PmHS2 is a 
bifunctional enzyme with both N-acetylglucosaminyltransferase and D-
glucuronyltransferase in Pasteurella multocida Types A, D, and F.  Both of the 
recombinant proteins were prepared in large quantities.  Characterization of KfiA reveals 
that its enzymatic activity is independent of the size of the acceptor substrates but a 
particular structure in the natural donor UDP-N-acetylglucosamine is required to bind 
KfiA.  UDP-N-trifluoroacetylglucosamine, a derivative of UDP-N-acetylglucosamine, 
was recognized by KfiA and employed to synthesize unnatural HS backbones containing 
N-trifluoroacetylglucosamine residues.  The synthesized oligosaccharides range from 
 ii
trisaccharide to undecasaccharide with a yield of 100 µg to milligram scales.  The 
controlled N-sulfation on HS backbones was achieved by selective removal of N-
trifluoroacetyl groups and a subsequent N-sulfation with N-sulfotransferase.  The 
synthesized octasaccharide backbone with defined N-sulfation was further modified with 
a collection of HS biosynthetic enzymes and yielded a bioactive octasaccharide binding 
to antithrombin.  The results of this study open a new approach for the de novo synthesis 
of structure-defined HS oligosaccharides.       
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Chapter I. Introduction 
Section 1. Structure of heparan sulfate 
1. Overall structure of heparan sulfate 
Heparan sulfate (HS) is a linear polymer that belongs to a family of macromolecules 
known as glycosaminoglycans (GAGs).  GAGs are ubiquitous macromolecules 
associated with the cell surface and in the extracellular matrix (ECM).  They are 
classified into four subclasses: chondroitin sulfate (CS), keratan sulfate (KS), hyaluronic 
acid (HA) and heparan sulfate (HS). 
HS consists of alternating hexuronic acid (D-glucuronic acid/GlcA or L-iduronic 
acid/IdoA) and D-glucosamine (GlcN) units carrying sulfo groups, attached via 1?4 
linkages.  HS is structurally diverse through various modifications on the repeating 
disaccharide unit.  The hexuronic acid residue can be either GlcA or IdoA depending 
upon the configuration at the C5 position, and its C2 position can be O-sulfated.  The 
GlcN residue can be N-acetylated (GlcNAc), N-sulfated (GlcNS) and/or O-sulfated at its 
C3 and C6 positions (figure 1). 
O
COOH
OH
O
O
CH2O
N
O OR
HR'
O
R
R
 
Figure 1. Disaccharide repeating unit of heparan sulfate 
R= H or SO3-, R’= H, Ac or SO3- 
Under physiological conditions, HS exists in the form of heparan sulfate 
proteoglycans (HSPGs).  HSPG consists of a core protein attached by one or more HS 
chains.  Based on their cellular locations, HSPGs are classified into two groups: 
membrane-bound HSPGs (syndecans and glypicans) positioned on the cell surface, and 
secreted HSPGs (perlecans, agrins and collagen XVIII) located in the ECM (Iozzo 2001). 
 
2. Structural analysis of heparan sulfate 
Unlike protein and nucleic acid preparative techniques, the methods for preparing and 
purifying HS are highly limited.  Specifically, the heterogeneity of HS and lack of a fast 
automated method to sequence HS complicate the structure-function relationship study of 
HS.  The most commonly used approach for analyzing the structure of HS is to degrade 
the polysaccharide into disaccharides or oligosaccharides.  The resultant disaccharides 
or oligosaccharides are identified by various analytical techniques such as high 
performance liquid chromatography (HPLC), mass spectrometry (MS) and capillary 
electrophoresis (CE). 
Depolymerization of HS can be achieved with enzymatic or chemical methods.  
Heparin lyases are endoglycosidases that have different substrate specificities (Desai 
1993).  As shown in figure 2, heparin lyase I cleaves the glycosidic linkage between 
2-O-sulfated IdoA and GlcNS within HS where highly sulfated domains reside (Liu 
2002).  Heparin lyase III cleaves the glycosidic linkage between GlcA and either 
GlcNAc or GlcNS which belongs to the less sulfated domains within HS.  Heparin lyase 
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II, however, demonstrates more flexibility and cleaves at the sites that either heparin 
lyase I or III recognizes.  Using heparin lyases make it possible to directly analyze the 
degradation products.  This may be explained by the generation of a ∆4,5-unsaturated 
uronic acid at the non-reducing end of the product that has a characteristic absorbance at 
232 nm.  On the other hand, it is impossible to assign GlcA or IdoA in the precursor 
structure, because the generation of this uronic acid residue leads to a loss of structural 
information on the C5 configuration of the hexuronic acid residue.  It is also unlikely to 
reach completion for the enzymatic degradation of HS, therefore raising a concern of 
underestimation of some disaccharide species. 
O
CH2OR
OR
NHSO3-
O O
O
COOH
OH
OSO3-
O
O
CH2OR
OR
NHR'
O O
O
OH
OR
O
Heparin Lyase I
COOH
Heparin Lyase II
O
CH2OR
OH
NHR'
O O
O
OH
OH
O
COOH
Heparin Lyase III
O
CH2OR
OR
NHR'
O
OH
O
COOH
OR
OR
O
Δ4,5-unsaturated uronic acid,
displays absorbance at UV @ 232nm  
Figure 2. Heparin lyases degrade HS with different substrate specificities (Liu 2002) 
R= H or SO3-, R’= H, Ac or SO3-
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Nitrous acid degradation is commonly used as the chemical approach to depolymerize 
HS (figure 3).  The reaction selectivity is pH dependent.  At low pH (pH 1.5), nitrous 
acid predominantly reacts with GlcNS, while at high pH (pH 4.5-5.5) it primarily reacts 
with GlcN (Shively 1976).  Either way the reaction will generate 2,5-anhydromannose 
which can be further reduced to 2,5-anhydromannitol.  Notably, nitrous acid degradation 
retains the structure of GlcA/IdoA and, therefore, allows the determination of the C5 
configuration of hexuronic acid on the HS chain.  But the tradeoff is that additional 
radioactive or fluorescent label is required to monitor the resultant disaccharides.  
Liquid chromatography-mass spectrometry (LC-MS) is a recently developed approach 
that combines the physical separation capability of liquid chromatography with the mass 
analysis capability of mass spectrometry (Tomer 1994).  It can be used with nanospray 
sources and has a high specificity and sensitivity.  Most importantly, LC-MS can 
overcome the difficulty arising from the lack of radioactive or fluorescent labels. 
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OO
OOHOR
CH2OR
O
ORNHSO3-
COOH
O
HNO2, pH 1.5
O
OR
CH2OR
CHO
O
OOH
OR
COOH
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O
O
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CH2OH
O
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O
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COOH
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OOHOR
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O
COOH
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OO
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O
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O
COOH
HNO2, pH 4.5
O
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O
+
+
O
OOH
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COOH
OH
NaBH4
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CH2OH
O
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O
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COOH
OH
Low pH nitrous degradation
High pH nitrous degradation
 
 
Figure 3. Nitrous acid degradation of heparan sulfate (Liu 2002) 
R= H or SO3-
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Section 2. Biological functions of heparan sulfate and the defined bioactive domains 
 
HS is a charge-rich polymer widely distributed on the cell surface and in the ECM.  It 
plays crucial roles in numerous physiological and pathological processes through 
electrostatic interactions with proteins (Esko 2002).  Some biologically active 
oligosaccharide structures on the HS chain have been identified. 
 
1. Antithrombotic effect and the antithrombin (AT)-binding domain 
 
Heparin has been the top choice for the treatment of arterial and venous thrombotic 
disorders over a half century.  Blood coagulation is a cascade process (figure 4) (Broze 
1995).  When the coagulant cascade is initiated intrinsically, the contact factors such as 
factor XII is exposed to the surface and converted to its active form, factor XIIa.  Factor 
XIIa is a serine protease and goes on to catalyze the activation of the next zymogen until 
prothrombin is converted to thrombin.  The extrinsic pathway is initiated by binding of 
factor VIIa to tissue factor which is followed by a series of proteolytic reactions, leading 
to the generation of thrombin.  In both pathways, thrombin cleaves fibrinogen into fibrin 
and the polymerization of fibrin leads to an insoluble clot. 
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Figure 4. Blood coagulation cascade 
 
The cascade is triggered by either intrinsic pathway or extrinsic pathway.  The two routes 
converge on the generation of thrombin which leads to blood clotting. 
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The anticoagulant activity of heparin was first discovered in an extract of dog liver at 
Johns Hopkins University more than ninety years ago (McLean 1916).  Heparin/HS 
modulates blood coagulation through the inhibition of the serine-proteases in the 
coagulation cascade, including factor Xa and thrombin.  The inhibition is either direct or 
indirect through its binding with the protease inhibitor antithrombin (AT) (Lever 2002).  
Rosenberg and colleagues found that AT forms a 1:1 complex with thrombin (Rosenberg 
1973).  The research demonstrated that the addition of exogenous heparin markedly 
promotes the formation of this complex which decelerates blood coagulation.  It was 
suggested that heparin binding with AT causes a conformational change of AT which 
leads to a more favorable exposure of the arginine reactive sites on this inhibitor, 
allowing a rapid interaction with thrombin. 
A well-defined structure (figure 5) has been determined to be crucial for the 
AT-binding capability of heparin/HS (Lindahl 1980; Atha 1985).  The AT-binding 
domain is a pentasaccharide sequence of -GlcNAc(or 
GlcNS)6S-GlcA-GlcNS3S±6S-IdoA2S-GlcNS6S- and is the essential motif conferring 
anticoagulant activity to heparin/HS.  The critical 3-O-sulfation on the GlcNS3S±6S 
residue is catalyzed by 3-O-sulfotransferase 1 (3OST1) or 3-O-sulfotransferase 5 (3OST5) 
(Shworak 1999; Xia 2002). 
The pentasaccharide alone can effectively regulate the activity of factor Xa, while a 
ternary complex of HS, AT and thrombin was proposed to inactivate thrombin.  
Therefore, a longer HS fragment is necessary to accommodate both AT and thrombin in 
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order to inhibit the activity of thrombin (Olson 1992). 
 
 
 
 
Figure 5. AT-binding pentasaccharide 
 
The pentasaccharide contains a critical 3-O-sulfation (in red) in the middle glucosamine residue.  
Its AT-binding affinity is 30 nM, while the same pentasaccharide, except lacking this important 
3-O-sulfation (in red), has a binding affinity of 500 μM (Atha 1985). 
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2. Cell proliferation/differentiation and the fibroblast growth factor (FGF)-binding 
domain 
 
The FGF family of proteins form a family of approximately 20 structurally related 
polypeptides which are involved in a number of biological regulations in cell growth and 
development (Basilico 1992).  The FGF signaling pathway is initiated by binding of 
FGF with its tyrosine kinase receptor (FGFR) on the cell surface, leading to the 
dimerization of FGFR and the phosphorylation/activation of downstream enzymes.  The 
process is modulated through an interaction between FGF, FGFR and HS molecules.  
HS has been implicated to enhance the formation of FGF-FGFR complexes and stabilize 
FGFR oligomers (Brickman 1998; Kwan 2001). 
FGF1 and FGF2 are the two mostly investigated FGF proteins.  A protein 
crystallization technique has been employed to solve the structure of the complex of HS 
oligosaccharides and these two proteins.  As shown in figure 6, the 2-O-sulfate on 
iduronate (IdoA2S) and N-sulfate on glucosamine (GlcNS) are critical for both FGF1 and 
FGF2 binding (Tabeur 1999), while additional 6-O-sulfate on glucosamine (GlcNS6S) is 
only necessary for FGF1 binding (Guerrini 2002).  It is noteworthy that FGFR also 
contains a HS-binding site which interacts with GlcNS6S (Loo 2001), suggesting that, in 
order to trigger the dimerization of FGFR and the downstream cell signaling, the active 
HS fragment should be long enough (figure 6, n>5) to include two binding motifs for 
both FGF and FGFR.  Further investigation of the HS structures involved in other 
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growth factor signaling pathway was also initiated.  For example, a systematic 
investigation of the HS binding structures for various heparin-binding growth factors was 
made by subjecting an octasaccharide library to affinity chromatography (Ashikari-Hada 
2004).  Some octasaccharides were found capable of releasing FGF2 and FGF10 from 
their complex with HS, suggesting a new approach to specifically regulate bindings of the 
growth factors to HS.  
 
 
 
 
Figure 6. Repeating disaccharide unit –IdoA2S-GlcNS6S- implicated in FGF binding 
 
n>2 needed for binding to FGF1 (-IdoA2S-GlcNS6S-) and FGF2 (-IdoA2S-GlcNS-).  
n>5 needed for dimerization and cell signaling. 
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3. Viral infection and the herpes simplex virus (HSV)-1 glycoprotein D-binding domain  
 
The recognition and binding of host cells is the first step for virus to establish an infection.  
Since HS is ubiquitously expressed on the surface of most animal cells, it is not 
surprising that HS often serves as a natural bridge for virion particles to attach and invade 
target cells.  It has been demonstrated that HS is involved in the infection of many 
viruses including human immunodeficiency virus (HIV), hepatitis C virus (HCV), dengue 
virus and herpes simplex virus (HSV) (Liu 2002).  As a result, the study on the structure 
and mechanism of HS-virus interaction has attracted considerable attention from both 
scientific and pharmaceutical communities.  For example, the involvement of HS in 
HSV-1 infection has been well characterized in the last two decades. 
HSVs are neurotropic and neuroinvasive viruses.  The viral particles enter and reside 
in the human nervous system, accounting for their persistent existence in the human body.  
An infection by HSV is marked by watery blisters in the skin or mucous membranes of 
the mouth, lips or genitals.  HSV-2 is often associated with genital herpes, whereas 
HSV-1 is commonly associated with herpes outbreaks of the face known as cold sores or 
fever blisters.  After the primary infection, HSV becomes latent in the nerve cells.  
Some infected patients may experience sporadic episodes of viral reactivation when the 
virus travels back to the skin via the nerve’s axon and replicates again (Ryan 2004). 
As for the mechanism of HSV-1 infection, it is now believed that HSV-1 first attaches 
to target cells through the interaction between its envelope glycoprotein gC/gB and HS on 
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the surface of host cells (figure 7) (Trybala 1994). 
 
 
Figure 7. The binding and entry mechanism of HSV-1 virus (Liu 2002) 
 
Step 1. Virus is attached to target cells via the interaction between viral glycoprotein B, C (gB, gC) 
and the HS on the surface of host cells. 
 
Step 2. Viral glycoprotein D (gD) interacts with the entry receptor and/or 3-O-sulfated HS. 
 
Step 3. The interaction in step 2 triggered uncharacterized fusion of cell membranes which leads 
to the entry of virus. 
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Once the contact is established, the binding between viral envelope glycoprotein gD 
and cell surface entry receptor such as 3-O-sulfated HS results in the fusion of the virus 
and cell membranes.  This is evident by the observation that wild type CHO cells which 
are resistant to HSV-1 infection become susceptible to infection after transfected with the 
cDNA of 3OST3 (Shukla 1999).  It is important to note that the transfection of the 
plasmid expressing 3OST1 did not lead to HSV-1 entry and 3OST1 modified HS does not 
bind to gD, suggesting that the 3-O-sulfated HS involved in HSV-1 infection contains a 
specific 3-O-sulfation pattern.  A gD-binding octasaccharide was later isolated from a 
3OST3-modified octasaccharide library with a binding affinity of 18 µM.  Based on the 
results from nanoelectrospray ionization mass spectrometry and matrix-assisted laser 
desorption/ionization mass spectrometry, a proposed heptasulfated sequence of 
ΔUA-GlcNS-IdoA2S-GlcNAc-UA2S-GlcNS-IdoA2S-GlcN3S6S was assigned to this 
gD-binding octasaccharide (figure 8) (Liu 2002).  Directed by this information, 
Copeland and colleagues synthesized a HS octasaccharide with the purified 3OST3 
enzyme and a heparin octasaccharide in vitro.  It has a structure of 
ΔUA2S-GlcNS6S-IdoA2S-GlcNS6S-IdoUA2S-GlcNS3S6S-IdoA2S-GlcNS6S.  This 
3-O-sulfated octasaccharide was demonstrated to have a binding affinity to gD of 19 µM 
(very similar to that of the previously characterized gD-binding octasaccharide in figure 8) 
and was effective in blocking HSV-1 infection in a cell-based assay (Copeland 2008).  
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Figure 8. Structure of a gD-binding octasaccharide 
 
The octasaccharide contains a critical 3-O-sulfation (in red) at the reducing-end glucosamine 
residue.  It has a binding affinity to gD of 18 µM (Liu 2002). 
 
4. Inflammation 
 
Inflammation is a protective response by the organism to harmful stimuli from the 
environment, such as pathogens, damaged cells, or irritants.  In the absence of 
inflammation, wounds and infections would never heal and progressive destruction of the 
tissue would compromise the survival of the organism.  However, inflammation which 
runs unchecked can also lead to a host of diseases.  It is for this reason that 
inflammation is normally tightly regulated by the body. 
In a typical inflammation response, leukocytes migrate from circulation to the injured 
area by attaching to activated endothelial cells.  Leukocyte trafficking is believed to be 
directed by the chemokines immobilized on the luminal surface of the endothelium 
(Middleton 2002).  It has been demonstrated that endothelial heparan sulfate participates 
in multiple steps in this process, including L-selectin binding, chemokine presentation to 
its receptors, and the transportation of chemokines across endothelium (Middleton 1997).  
The studies with mutant mouse models demonstrated that 
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N-deacetylase/N-sulfotransferase 1 (NDST1) deficient mice showed significantly 
impaired inflammatory response.  The proposed mechanism is that the undersulfated HS 
in the endothelial cells of mutant mice led to reduction in the presentation of chemokines 
on their surface, the weakening binding with L-selectin on neutrophil, and ultimately, less 
recruitment of leukocytes to the inflammation sites in vivo (Wang 2005). 
The multiple functions of HS in the process of inflammation suggest it has 
conceivable clinical applications in treating inflammatory diseases.  As a potential 
anti-inflammatory drug, HS has been tested against inflammatory bowel disease (IBD) in 
an animal test. Heparin pretreatment greatly reduced the inflammatory response in rats 
elicited by TNF-α administration through a CD11b dependent mechanism, as 
preincubation with an anti-CD11b mAb significantly diminished heparin binding (Salas 
2000).  In another two-period, randomized, double-blinded clinical study on asthma, the 
inhaled heparin attenuated the early and late asthmatic response in patients by an average 
of 40% and 36%, respectively, which suggests heparin has potential as an anti-asthma 
therapy (DianMant 1996). 
 
5. Tumor growth and metastasis 
 
Malignant cancer is a class of diseases in which a group of cells display the traits of 
abnormal and uncontrolled growth, invasion and metastasis (Hanahan 2000).  Because 
HSPGs and HSPG-degrading enzymes mediate cell-cell contact and modulate the 
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activities of growth and motility factors, they play a critical role in regulating tumor 
progression (Sasisekharan 2002). 
One of the hallmarks of the tumor cells is the sustained abnormal growth.  Cell 
surface HSPGs interact with numerous growth factors, facilitate the binding with their 
receptors, and therefore promote cell growth.  The sulfate groups on HS are critical to 
form the growth-factor binding sites on HSPGs.  Therefore, it is not surprising that the 
human sulfatase 1 (SULF1), which removes the important sulfate groups on HS and 
down-regulates cell growth signaling, is suppressed in breast, hepatocellular, pancreatic 
and many other cancers (Dai 2005). 
On the other hand, cell surface HSPGs were also reported to inhibit cancer invasion 
by keeping tight cell-cell and cell-ECM adhesion.  Low level of cell surface HSPGs was 
shown to correlate with high metastatic activity of tumor cells (Redini 1986) (Moczar 
1993).  Syndecan-1 on the cell surface was also determined to be a potent suppressor of 
metastasis by maintaining epithelial morphology (Leppa 1992).  For instance, uterine 
carcinoma and multiple myeloma have lowered expression level of syndecan-1 during 
their transition to invasive carcinoma (Sanderson 2001).  Furthermore, complementation 
of syndecan-1 in invasive B lymphoid cells enables their tight adhesion to type I collagen 
and blocks their ability to invade collagen gels (Liebersbach 1994), while transfection of 
another cell surface HSPG, glypican-1, could not achieve these effects (Liu 1998), 
indicating that different HSPGs have distinct anticancer capability. 
Heparanase is an endo-beta-D-glycosidase acting at both the cell surface and within 
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the ECM to degrade HS molecules into the polysaccharides with a shorter size.  Its 
overexpression was found in many human tumors examined, including carcinomas of the 
colon, thyroid, liver, pancreas, head and heck, salivary gland, nasopharyngs, leukemia, 
lymphoma and multiple myeloma (Ilana 2006).  It is postulated that an effective 
inhibitor of heparanase could serve as a potential anticancer drug.  Cell surface HSPGs 
help to the self-assembly and barrier function of ECM, as well as in cell adhesion and 
locomotion.  Cleavage of HS by over-expressed heparanase may, therefore, lead to ECM 
remodeling and tumor metastasis.  Direct evidence was provided in the studies in which 
transfection and over-expression of the heparanase gene led to promoted metastases of 
mouse melanoma, lymphoma and prostate carcinoma cells (Vlodavsky 1999) while 
heparanase gene silencing greatly suppressed tumor metastasis (Edovitsky 2004).   
Angiogenesis is a physiological process involving the growth of new blood vessels 
from pre-existing vessels.  Angiogenesis is a normal process in development and wound 
healing, as well as in cancer progression for tumor cells to provide sufficient nutrient for 
their growth.  Up-regulated heparanase expression in tumor cells may first directly 
destroy the subendothelial basement membrane (BM) by cleaving HS in the BM so that 
endothelial cells can invade and sprout in the early stage of angiogenesis.  Heparanase 
distribution was indeed revealed in capillaries but not in mature blood vessels with the 
immunohistochemical approach (Elkin 2001).  Furthermore, degradation of HS in the 
ECM may release HS-bound angiogenic growth factors, such as FGF2 and vascular 
endothelial growth factor (VEGF), from the ECM (Vlodavsky 1996).  These molecules 
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may cooperatively increase the proliferation and migration of endothelial cells and 
promote neovascularization. 
The multifaceted functions of HSPGs in cancer progression have considerable clinical 
implications for anti-cancer therapy.  With the availability of recombinant heparanase 
and high-throughput screening methods, a variety of heparanase inhibitors have been 
developed.  These inhibitors include the peptides competing with the HS binding 
domain of heparanase (Vlodavsky 2007), the small molecules targeting the catalytic 
domain of heparanase (Pan 2006), the monoclonal antibodies (Ferro 2004), and HS 
derivatives as mimetics of HS, such as maltohexaose sulfate (MHS) and 
phophomannopentaose sulfate, PI-88 (Parish 1999) (Ferro 2007). 
 
Section 3. Biosynthesis of heparosan 
 
1. Polysaccharide capsules of bacteria 
Polysaccharide capsules are found on the surface of a broad spectrum of bacterial species.  
Such a structure surrounding the microbial cell may protect bacteria from desiccation 
(Roberson 1992), help bacteria adhere to each other and form a protective biofilm 
(Costerton 1987), mediate bacteria-plant interaction (Denny 1991), and protect bacteria 
from specific and nonspecific host immunity (Roberts 1989) (Moxon 1990). 
Different from vertebrates, microbes produce the four types of polysaccharide 
(chondroitin, keratan, hyaluronan and heparason) without epimerization or sulfation 
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(table 1) (DeAngelis 2002). 
 
 
Postpolymerization modifications 
Polysaccharide Disaccharide repeat Vertebrates Bacteria 
Chondroitin →3)GalNAc(β1→4)GlcA(β1→ O-sulfated, epimerized 
none or 
fructose(β1→3)GlcA
Keratan →4)GlcNAc(β1→3)Gal(β1→ O-sulfated not reported 
Hyaluronan →3)GlcNAc(β1→4)GlcA(β1→ none none 
Heparason →4)GlcNAc(α1→4)GlcA(β1→
N-, 
O-sulfated, 
epimerized 
none 
 
Table 1. Structures of the vertebrate and microbial GAG repeating backbones (DeAngelis 
2002). 
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2. Heparosan glycosyltransferases in bacteria 
 
In bacteria, heparosan glycosyltransferases utilize uridine diphospho 
(UDP)-monosaccharide precursors (UDP-GlcNAc and/or UDP-GlcA) to synthesize the 
alternating sugar repeat with the presence of metal cofactors (manganese and/or 
magnesium ion) near neutral pH (figure 9).  Some of the microbial heparosan 
glycosyltransferases have been identified and characterized such as those in Escherichia 
and Pasteurella. 
 
 
Figure 9. Biosynthesis of heparosan 
 
GlcNAc and GlcA transferases incorporate GlcNAc and GlcA, step by step, into the growing 
heparosan backbone at its non-reducing end.  In E. coli K5, the two transferase activities are 
separately carried by KfiA and KfiC, while in P. multocida, PmHS2 is one of the bifunctional 
enzymes that have both activities. 
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Escherichia coli K5 capsular polysaccharide is composed of an unepimerized, 
unsulfated N-acetyl heparosan (Vann 1981).  It was reported that K5 capsule expression 
can enhance intestinal colonization by E. coli (Hérias 1997).  The region 2 of the E. coli 
K5 capsule gene cluster contains four genes, kfiA-D, which have been determined to be 
essential for heparosan biosynthesis (Petit 1995).  With biochemical analysis of the 
bacteria membrane and lysate, a 60-kDa protein, KfiC, was first identified to be a 
dual-function enzyme with both glucuronyltransferase and 
N-acetylglucosaminyltransferase activities (Griffiths 1998).  However, the same group 
reported two years later that the N-acetylglucosaminyltransferase is actually another 
protein, KfiA, which is encoded in the same gene cluster (Hodson 2000).  The 
recombinant KfiA protein was expressed and purified in large quantity by our group.  Its 
N-acetylglucosaminyltransferase activity was confirmed and its substrate specificities 
was determined (Chen 2006).  The glucuronyltransferase activity of KfiC has yet to be 
confirmed by the single sugar addition assay with the recombinant protein in vitro.  The 
predicted amino acid sequence of KfiD has homology to a number of nicotinamide 
adenine dinucleotide (NAD)-dependent dehydrogenase enzymes and was demonstrated to 
be a UDP-glucose dehydrogenase that catalyses the formation of UDP-glucuronic acid 
from UDP-glucose (Petit 1995).  The other deduced protein in the operon, KfiB, has not 
been assigned any enzymatic activity, but with Western blot analysis it has been 
suggested to stabilize the enzyme complex during the elongation process in vivo (Hodson 
2000).  Collectively, the four proteins KfiA-D encoded in the region 2 of the E. coli K5 
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capsule gene cluster work in concert to build the heparosan polysaccharide in E. coli K5. 
Pasteurella multocida is a type of Gram-negative bacteria and its type D capsular 
polysaccharide is the same as that of E. coli K5 (DeAngelis 2002).  The two heparosan 
synthases, PmHS1 (DeAngelis 2002) and PmHS2 (DeAngelis 2004), were identified to 
synthesize heparosan in P. multocida type D.  PmHS1 and PmHS2 are bifunctional 
glycosyltransferases polymerizing both GlcNAc and GlcA in vitro.  The mutagenesis 
study showed that PmHS1 possesses both a glucuronyl and a glucosaminyl transfer sites 
at different regions in one polypeptide chain (Kane 2006).   
Besides these bacterial enzymes, heparosan glycosyltransferases have also been 
identified in mammals.  They are known as HS polymerases and will be discussed in 
detail in Section 4.   
 
Section 4. Biosynthesis of heparan sulfate 
 
In mammals, HS backbone is built by multiple glycosyltransferases and further modified 
by additional HS biosynthetic enzymes, including N-deacetylase/N-sulfotransferases, 
epimerase, and O-sulfotransferases in the lumen of Golgi apparatus (Esko 2002).  After 
years of the sustained studies on these enzymes, many of them have been cloned and 
purified.  Much information about the pathway of HS biosynthesis and the substrate 
specificities of HS biosynthetic enzymes is also available. 
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1. Chain initiation 
 
HS biosynthesis is initiated in the Golgi apparatus after transfer of xylose (Xyl) from 
UDP-Xyl to the specific serine residues of a core protein catalyzed by xylosyltransferases 
(XTs).  UDP-Xyl is derived from the activated glucose, UDP-Glucose (UDP-Glc), by 
UDP-GlcA decarboxylase.  The attachment sites recognized by XT typically consist of a 
Ser-Gly dipeptide with one or more flanking acidic amino acid residues (Sugahara 2000).  
XT has type II transmembrane topology consistent with its location in Golgi where HS 
biosynthesis occurs.  Without XT, Chinese hamster ovary (CHO) cells were unable to 
synthesize HS and CS, suggesting that XT is necessary for initiating the biosynthesis of 
HS and CS (Esko 1985). 
Once the Xyl residue is linked to the core protein, a tetrasaccharide linkage 
(GlcA-β1,3-Gal-β1,3-Gal-β1,4-Xyl-β1-O-[Ser], figure 10) on the core protein will be 
formed after the sequential attachment of two D-galactose (Gal) residues by 
galactosyltransferases I and II (GalTI and GalTII) and a GlcA by glucuronosyltransferase 
I (GlcATI).  Both GalTI and GalTII use UDP-Galactose (UDP-Gal) as the donor 
substrate and they both show type II transmembrane topology (Sugahara 2000; Bai 2001).  
The general linkage region for GAG biosynthesis may undergo a series of sulfation and 
phosphorylation reactions which may regulate the biosynthesis of GAGs.  The Xyl 
residue can be phosphorylated at its C2 position, and the two Gal residues may be 
sulfated at their C4 or C6 positions (figure 10) (Gulberti 2005).  In an in vitro assay, 
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GalTI has no activity towards the C2-phosphorylated xyloside, suggesting this 
modification at Xyl may arrest the biosynthesis of some GAG chains (Jacquinet 2004).  
On the other hand, the sulfated Gal only occurs in the tetrasaccharide linkage of CS but 
not HS biosynthesis.  The studies concerning the substrate specificity of GlcATI also 
demonstrated that sulfation on the two Gal residues influenced the activity of 
glucuronyltransferase (Sato 2003; Seko 2003; Gulberti 2005).  Therefore, it is 
reasonable to propose that the sulfated Gal may provide a regulatory mechanism to 
control the rate of HS biosynthesis and may modulate the direction of the GAG assembly. 
 
 
 
 
Figure 10. The tetrasaccharide linkage in the biosynthesis of heparan sulfate 
 
R = H or PO3-, R’ = H or SO3- (SO3- only occurs in CS) 
 
The tetrasaccharide linkage domain (GlcA-β1,3-Gal-β1,3-Gal-β1,4-Xyl-β1-O-[Ser]) was 
sequentially built by four types of transferases.  XTs first place a Xyl to the core protein, 
followed by the attachment of two Gal residues by GalTI and GalTII, and a GlcA by GlcATI. 
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2. Chain elongation 
 
Both HS and CS biosynthesis use the same tetrasaccharide linkage sequence that is 
attached to the core protein.  However, the two routes diverge in the step in which the 
assembly of HS continues with the addition of GlcNAc by HS GlcNAc transferase I 
(GlcNAcTI) at the non-reducing end of the tetrasaccharide linkage.  It was suggested 
that two mammalian enzymes, EXTL2 (Kitagawa 1999) and EXTL3 (Kim 2001), 
possessed GlcNAcTI activity.  It is noteworthy that GlcNAcTI is an initiating GlcNAc 
transferase and different from HS GlcNAc transferase II (GlcNAcTII).  GlcNAcTII adds 
GlcNAc to the growing HS chain instead of the tetrasaccharide linkage.  EXTL2 and 
EXTL3 belong to the exostosin (EXT) gene family which includes EXT1, EXT2 and three 
EXT-like genes EXTL1, EXTL2 and EXTL3.  Both EXTL2 and EXTL3 demonstrated 
GlcNAcTI activity towards a synthetic analogue 
(GlcA-β1,3-Gal-β1-O-naphthalenemethanol) which mimics the tetrasaccharide linkage 
and the hydrophobic domain in the core protein (Kim 2001).  Interestingly, EXTL3 has 
also been shown to possess GlcNAcTII activity, indicating this enzyme may participate in 
both chain initiation and elongation processes (Kim 2001). 
The D-GlcNAc residue is first attached to the tetrasaccharide linkage.  This is 
followed by the alternate addition of GlcA and GlcNAc residues, which leads to the 
formation of HS backbone composed of 50-100 repeating disaccharide units (figure 9).  
The polymerization reactions may be catalyzed by EXT1 and EXT2 which are 
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bifunctional enzymes with both GlcATII and GlcNAcTII activities, noting that the 
GlcATII activity is distinct from the GlcATI activity in synthesizing the tetrasaccharide 
linkage.  Based on biochemical and genetic evidence, EXT1 and EXT2 are 
indispensable for each other to form a heterocomplex to maintain their enzymatic 
activities in the Golgi apparatus both in vivo and in vitro (McCormick 2000) (Kim 2003).  
Besides EXT1 and EXT2, it was also found that EXTL1 and EXTL3 have GlcNAcTII 
activity in vitro (Kim 2001).  One hypothesis is that EXTL1 and EXTL3 may regulate 
polymerization by competing with EXT1/EXT2 complex.  It is also possible that as 
there are a couple of redundant GlcNAcTII enzymes (EXT1/EXT2, EXTL1, EXTL3) 
available, the GlcATII reaction which adds GlcA to the growing sugar chain is a 
rate-determination step in HS elongation. 
 
3. Backbone modifications 
 
The length of HS backbone varies and is controlled by regulating the activities of EXT 
family enzymes.  The HS chain diversity is further complicated as the backbone can be 
modified by a series of HS biosynthetic enzymes, including 
N-deacetylase/N-sulfotransferase (NDST), C5-epimerase (C5-epi), 2-O-sulfotransferase 
(2OST), 6-O-sulfotransferase (6OST) and 3-O-sulfotransferase (3OST) as illustrated in 
figure 11. 
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Figure 11. Heparan sulfate backbone modifications and its biosynthetic enzymes 
 
A. HS backbone is modified by NDST, C5-epi, 2OST, 6OST and 3OST in sequence, leading to 
the HS structures with various sulfation patterns. 
 
B. HS biosynthetic enzymes change the structure of HS with geometric specificities. The 
modified positions are shown in blue. 
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 N-deacetylase/N-sulfotransferase 
NDST converts the N-acetyl group to N-sulfate group in a GlcNAc residue.  The 
modification by NDST is the first step of the backbone modifications.  In fact, NDST is 
a dual-action enzyme with two distinct functions: N-deacetylation and N-sulfation 
(Perrimon 2000). 
The conversion of GlcNAc to GlcNS is believed to be a prerequisite step for 
subsequent epimerization and O-sulfations, and is, therefore, a decisive step in HS 
modifications.  Controlled by the activity of NDST, there are NS domains (GlcNS rich), 
NA domains (largely unmodified GlcNAc) and NS/NA (mixture of GlcNS and GlcNAc) 
domains in the HS polysaccharide chain.  NDST has four isoforms, NDST1, NDST2, 
NDST3 and NDST4 with different enzymatic activity and expression patterns (Aikawa 
2001).  The redundancy and difference among NDST isoforms may lead to various 
sulfation patterns in the HS chain. 
The polypeptide chain of NDST has a type II transmembrane topology and can be 
divided into four domains: a cytoplasmic region, a transmembrane region, a stem region, 
followed by the catalytic domain where the independent active sites for N-deacetylase 
and N-sulfotransferase activities are located.  The truncated NDST enzymes with only 
N-deacetylase or N-sulfotransferase active site were constructed and they demonstrated 
respective enzymatic activities (Kakuta 1999; Duncan 2006).  The transmembrane and 
stem regions of NDST are believed to help localize it in Golgi. 
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The crystal structure of the N-sulfotransferase domain of NDST1 was solved with 
adenosine-3’, 5’-diphosphate (PAP) (figure 12) (Kakuta 1999).  The overall structure of 
NDST1 is roughly spherical and contains an open cleft with a hydrophilic surface where 
a HS substrate as large as hexasaccharide can bind.  The 5’-phosphate binding loop 
(PSB-loop) and α6 defines a cavity where adenosine 3'-phosphate 5'-phosphosulphate 
(PAPS) is bound.  Superimposition of the crystal structures of NDST1 and estrogen 
sulfotransferase (EST) suggests that Lys-614 of NDST1 and Lys-48 of EST function 
similarly as a proton donor in the mechanism of the action of these two enzymes (Kakuta 
1997) (Kakuta 1998).  Lys-614 is believed to be critical in N-sulfotransferase reaction 
also because it is a conserved residue among other HS sulfotransferases and the results 
from site-directed mutagenesis confirmed that it is essential for NDST1 to be active 
(Sueyoshi 1998).   
   
 
Figure 12. Overall structure and the PAPS-binding site of NDST1 (Kakuta 1999). 
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Unlike the N-sulfotransferase domain, less information about the N-deacetylase 
domain of NDST is known and this domain has hardly any homology to other 
carbohydrate deacetylases.  Various isoforms of NDST are distinct in the activity of 
N-deacetylase, suggesting it may determine the substrate specificity and regulate the 
modifications of HS backbones.  Indeed, various isoforms of NDST overexpressed in 
human embryonic kidney 293 cells individually resulted in the synthesis of HS with 
different sulfation patterns (Pikas 2000).  Recently the region of NDST2 that carries the 
N-deacetylase activity was located to its N-terminal domain (Ala66-Pro604), which helps 
further elucidate the mechanism of the function of NDST (Duncan 2006). 
 
Glucuronyl C5-epimerase 
Following N-deacetylation and N-sulfation, glucuronyl C5-epimerase (C5-epi) acts on the 
GlcA residue and interconverts its C5 configuration between D-GlcA and L-IdoA in a 
fashion of a reversible two-step process (figure 13).  A carbanion intermediate is first 
produced by deprotonation of C5 on the GlcA residue.  This is followed by protonation 
again at the C5 position but stereochemistry is changed such that the carboxyl group is 
shifted across the plane of the sugar ring (Hagner-McWhirter 2000).  As for substrate 
specificity, an adjacent GlcNS residue at the non-reducing end of the substrate (GlcA or 
IdoA) must be recognized by C5-epi (Esko 2001). 
 
 31
 
 
Figure 13. Reversible C5 epimerization between GlcA and IdoA catalyzed by C5-epi 
 
IdoA residues promote the conformational flexibility of HS, because the pyranose 
ring of IdoA can adopt more conformations than that of GlcA does (Mulloy 2000).  IdoA 
residues also complicate the structure diversity of HS.  2OST is believed to 
preferentially sulfate C2 on IdoA leading to the synthesis of HS with distinct sulfation 
patterns.  Particularly, C5-epi and 2OST are proposed to work synergistically and form a 
complex in vivo (Pinhal 2001).  In addition, 2-O-sulfated IdoA was resistant to 
conversion back to GlcA, indicating that C5-epi/2OST complex may achieve higher 
efficiency of modification (Jacobsson 1984).    
To date only one isoform of C5-epi has been found in almost all species examined 
except for fish.  Conserved C-terminal lysine residues in C5-epi may act as proton 
donors/acceptors in the reversible protonation/deprotonation reaction (Crawford 2001).  
Absence of IdoA in the HS chain in C5-epi deficient mice suggests that C5-epi is the only 
enzyme to produce HS containing IdoA and/or 2-O-sulfated IdoA (IdoA2S).  C5-epi 
deficient mice afforded poorly developed lungs and died immediately after birth due to 
respiratory failure, suggesting that C5-epi is a critical enzyme involved in development 
(Li 2003). 
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Uronosyl 2-O-sulfotransferase 
2-O-sulfation is the only sulfation occurring on the uronic acid residues in the HS chain 
and is important for the interactions between HS and a variety of proteins, such as, FGF 
(figure 6) (Tabeur 1999).  The reaction is catalyzed by the uronosyl 2-O-sulfotransferase 
(2OST) which acts with both IdoA and GlcA residues.  When provided with a substrate 
with both uronic acid units, 2OST, however, strongly favors the 2-O-sulfation of IdoA in 
line with its stronger affinity for IdoA-containing substrates (Rong 2001). 
Similar to C5-epi, there is one isoform of 2OST in most species.  As the crystal 
structure of 2OST has not been solved, the mechanism of its action remains unclear.  
Nevertheless, its biological importance is clear from genetic studies in 2OST deficient 
mice which die due to defective kidney development (Merry 2001).  The different 
phenotypes between 2OST deficient mice and C5-epi deficient mice suggest that 
2-O-sulfation in the HS chain has its particular biological effects (Li 2003). 
 
Glycosaminyl 6-O-sulfotransferase 
There are two positions (6-OH and 3-OH) on the glucosamine residues of HS chain 
available for O-sulfation.  Glycosaminyl 6-O-sulfotransferase (6OST) acts on 6-OH and 
transfers a sulfo group from PAPS to the glucosamine residue.  Three isoforms of 6OST 
(6OST1, 6OST2 and 6OST3) have been identified and they share 50-55% sequence 
homology.  Their sulfotransferase domains are more conserved and N- and C-termini are 
more variable (Habuchi 1998).  Some insights into the substrate specificity have been 
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gained from studies of recombinant enzymes using various O-desulphated poly- and 
oligo-saccharides as substrates (Habuchi 2000) (Smeds 2003).  The HS containing 
-IdoA-GlcNS- seems to be a better substrate for 6OST1 than that containing 
-GlcA-GlcNS-, while 6OST2 and 6OST3 appear more promiscuous and utilize both 
disaccharide structures.  Recent studies suggested that all the three isoenzymes can also 
modify GlcNAc units (Zhang 2001) (Smeds 2003).  Although the three isoforms of 
6OST have relatively similar substrate specificity, their expression patterns are variable.  
6OST1 expression in liver is higher than other tissue, 6OST2 is predominantly found in 
brain and spleen, and 6OST3 is ubiquitous (Habuchi 2000). 
6OST is important in HS modification as HS lacking 6-O-sulfation has no 
anticoagulant activity and loses its capability to trigger FGF signaling (Pye 1998).  
Knocking out both 2OST and 6OST disrupts the development of tracheal system in 
Drosophila, indicating 6OST is important for HS-mediated FGF activity and for 
maintaining the whole O-sulfation level of HS chain (Kamimura 2006). 
 
Glucosaminyl 3-O-sulfotransferase 
The final and most rare step in HS modifications is believed to be 3-O-sulfation catalyzed 
by 3-O-sulfotransferase (3OST).  The 3-O-sulfation occurs predominantly in heavily 
sulfated regions of HS, because the enzyme interacts with numerous sulfate groups of the 
polysaccharide substrate (Liu 2002).  As the last step in HS biosynthesis, it is 
conceivable that 3-O-sulfation directly determines the unique structures and functions of 
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HS, such as the AT-binding site and gD-binding site discussed previously. 
There are totally seven isoforms of 3OST identified to date (Shworak 1999).  3OST1 
and 3OST5 share 53% identity.  3OST2, 3OST3A, 3OST3B, 3OST4 and 3OST6 share 
about 70% identity.  Particularly, 3OST3A and 3OST3B are nearly identical in their 
sulfotransferase domain (Liu 2002).  The seven isoenzymes have different expression 
patterns.  3OST1 is highly expressed in heart, brain, lung and kidney.  3OST2 and 
3OST4 are mainly expressed in brain.  Both 3OST3A and 3OST3B are found in heart, 
lung, liver and kidney, but only 3OST3A exists in placenta and only 3OST3B is 
expressed in brain.  3OST5 is found in brain, spinal cord and skeletal muscle, while 
3OST6 is expressed in liver and kidney (Shworak 1999). 
3OST isoenzymes have respective substrate specificities with significant biological 
consequences (table 2).  Particularly, 3OST1 generates GlcA-GlcNS3S±6S within the 
AT-binding structure (Shworak 1997) and 3OST2, 3, 4, and 6 produce 
IdoA2S-GlcNS3S±6S, the glycoprotein gD-binding structure to assist HSV infection (Liu 
1999; Wu 2004).  3OST5 is promiscuous and generates a unique disaccharide structure 
IdoA-GlcNS3S±6S besides the two domains mentioned above (Xia 2002).  The results 
from the disaccharide analysis of the 3OST2-modified HS also suggests that 3OST2 
transfers sulfate to GlcA2S-GlcNS±6S (Liu 1999). 
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Substrate Related 3OST Product Biological function 
GlcA-GlcNS±6S 3OST1 and 3OST5 GlcA-GlcNS3S±6S AT-binding/anticoagulant
IdoA2S-GlcNS±6S 3OST2,3,4,6 and 3OST5 IdoA2S-GlcNS3S±6S gD-biding/HSV infection
IdoA-GlcNS±6S 3OST5 IdoA-GlcNS3S±6S Unknown 
GlcA2S-GlcNS±6S 3OST2 GlcA2S-GlcNS3S±6S Unknown 
 
Table 2. Substrate specificities of 3OSTs 
 
The crystal structure of 3OST1 has been solved in a binary complex with PAP (figure 
14) (Edavettal 2004).  The complex is roughly spherical with a large open cleft and 
similar to the overall fold of the sulfotransferase domain of NST1 (Kakuta 1999).  The 
large open cleft was suggested to be the HS-binding site.  The structure also reveals 
residues in the PAPS binding site that are critical for binding with the 5’-phosphate and 
3’-phosphate of PAPS via a number of hydrogen bonding interactions.  In addition, 
site-directed mutagenesis analyses suggest that residues Arg-67, Lys-68, Arg-72, Glu-90, 
His-92, Asp-95, Lys-123, and Arg-276 are essential for the enzymatic activity of 3OST1 
(Edavettal 2004). 
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Figure 14. The crystal structure of 3OST1 (Edavettal 2004) 
 
A. Stereo ribbon diagram of the structure of 3OST1 
 
B. Stereo diagram of the PAPS-binding site of 3OST1 with PAP bound 
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The crystal structure of 3OST3 was also reported in a ternary complex with PAP and 
a tetrasaccharide substrate (Moon 2004) (figure 15A).  The catalytic domain 
(Gly139-Gly406) of 3OST3 is spherical and remarkably similar to that of 3OST1.  A 
major difference is the structure of the loop formed by the disulfide bond between 
Cys351 and Cys363 in strands 9 and 10 of the C-terminal sheet of 3OST3.  The 
additional residues (Ala355-Gly357) in 3OST3 cause the loop to swing in the direction of 
the open cleft.  However, replacing the disulfide bond loop of 3OST1 (Cys260-Cys269) 
with that of 3OST3 (Cys351-Cys363) does not alter its substrate specificity, indicating 
the difference in this loop does not directly contribute to the substrate recognition.  
Gln255 and Lys368 lie within the hydrogen bonding distances to the carboxyl and sulfate 
groups of the uronic acid of the tetrasaccharide acid.  Mutational analysis suggests that 
these residues are critical for the substrate recognition of 3OST3.  Glu184 is very close 
to the 3-OH group of the substrate and conserved among NSTs and 3OSTs.  It is 
conceivable that it may function as a catalytic base to deprotonate the 3-OH for 
nucleophilic attack on the sulfate group (figure 15B).  Indeed, mutations of this 
glutamate residue lead to a complete loss of the sulfotransferase activities for NST1 
(Kakuta 2003) and 3OST3 (Edavettal 2004) and a 99.9% loss for 3OST3 (Moon 2004). 
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Figure 15. The crystal structure of 3OST3 (Moon 2004) 
 
A. Ribbon diagram of the crystal structure of ternary complex 3OST3/PAP (blue)/tetrasaccharide 
(green) and sequence alignment of human 3OST3 and mouse 3OST1 
 
B. Active site of 3OST3 with PAPS superimposed. Glu184 is shown in close contact with the 
3-OH group of the glucosamine residue of the tetrasaccharide substrate 
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With site-directed mutagenesis, a recent study found that Ser120 and Ala306 in 
3OST5 are critical to control its substrate specificity (Xu 2008).  When one of these two 
residues or both were converted to the corresponding ones in 3OST1, 3SOT5 began to 
generate more AT-binding sites and less gD-binding sites, demonstrating the feasibility to 
tailor the substrate specificities of 3OST.  In addition, the solved crystal structure of 
3OST5 in this study (figure 16) (Xu 2008), along with the crystal structures of 3OST1 
(Edavettal 2004) and 3OST3 (Moon 2004), have given insights in the mechanisms used 
by 3OST isoforms to dictate the substrate specificity.  It has been proposed that the 
isoenzymes use two sites, the catalytic domain and the gate, to select appropriate sugar 
substrates.  The catalytic domain is homologous among 3OST isoforms, while the gate 
residues are distinct and control the substrate specificity (Xu 2008).   
 
Figure 16. Ribbon diagram of the crystal structure of human 3OST5 with bound PAP (Xu 
2008) 
 40
Using 3OST knock out mice is an important approach to study the biological 
functions of 3OST in vivo.  The 3OST1 knock out mice was established showing 
profound phenotypes (HajMohammadi 2003).  Although 3OST1 deficient mice suffered 
from postnatal lethality, they did not exhibit any different phenotype in anticoagulation, 
indicating that the anticoagulant HS is not a major hemostatic regulator like AT in vivo.  
Nevertheless, the specific postnatal lethality in 3OST1 deficient mice suggests that 
3OST1 participates in some other profound biological processes. 
 
Section 5.  Chemical and enzymatic synthesis of anticoagulant heparan sulfate 
 
1. Chemical synthesis 
 
The significant medical potential of HS makes it the most studied molecule among GAGs.  
Over the past twenty years, numerous syntheses of native HS, HS oligosaccharides and 
HS derivatives have been reported and reviewed (Gama 2005; Linhardt 2007 a; Linhardt 
2007 b).  Chemical synthesis has been the major route to obtain structurally defined 
heparin and HS oligosaccharides.  Common strategies of chemical synthesis require 
efficient manipulation of protecting groups and stereoselective glycosylation, which 
relies on the appropriate leaving group at the anomeric (C1) position and the substituent 
at C2 position of the glycosyl donor (Karst 2003).  The synthesis of HS also depends on 
available tailor made monomers.  A “modular approach for HS synthesis” was 
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developed to prepare all combinations of monosaccharide building blocks (Haller 2001).  
Linhardt and colleagues used heparin lyase to depolymerize HS as an alternative 
chemoenzymatic approach for the preparation of various disaccharide building blocks 
(Yalpani 1996). 
The most successful synthetic HS oligosaccharide has been Arixtra, a chemically 
synthesized AT-binding pentasaccharide (figure 5) marketed as an anticoagulant drug in 
both the United States and Europe (Vuillemenot 1999).  Arixtra is a specific factor Xa 
inhibitor used in clinic to prevent venous thromboembolic incidents during surgery.  Its 
derivative was also synthesized as a chemically more accessible analogue where O-sulfo 
groups replace the N-sulfo groups in the glucosamine residues and O-methyl groups are 
introduced to substitute hydroxyl groups (Westerduin 1994).  However, Arixtra 
possesses lower anticoagulant activity than heparin because it is too short to harbor both 
anti-Xa and anti-thrombin activities.  Longer oligosaccharides with more than sixteen 
sugar units are believed necessary to form an effective ternary complex between HS 
oligosaccharide, AT and thrombin (Lane 1984).  Since the thrombin-binding domain is 
not restricted to any specific structures, the interaction between heparin and thrombin is 
believed to be non-specific and other linear oligosaccharides also have potential to bind 
thrombin (Olson 1991).  Petitou and colleagues reported the synthesis of an HS 
analogue with seventeen saccharide units (figure 17) (Petitou 1999).  To simplify the 
synthesis, hydroxyl groups were methylated and N-sulfo groups were replaced with 
O-sulfo groups in this compound.  With regard to the concern about side effects, the 
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heptadecasaccharide does not interact with platelet factor 4 (PF4) which is related to 
heparin-induced thrombocytopaenia (HIT) (Petitou 1999). 
 
 
 
 
 
Figure 17. A heptadecasaccharide with both anti-Xa and anti-thrombin activities (Petitou 
1999) 
 
This heptadecasaccharide contains a highly sulfated thrombin-binding domain (T-domain), a 
neutral hexasaccharide linkage domain (Linkage) and an AT-binding domain (A-domain). 
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2. Enzymatic synthesis 
 
Several mammalian and bacterial HS glycosyltransferases have been identified and 
harnessed as practical enzymatic tools to catalyze the polymerization of the activated 
sugar precursors.  These enzymes offer an alternative approach to synthesize HS 
backbone.  Busse and Kusche-Gullberg used recombinant soluble EXT1 and EXT1/2 
complex on exogenous oligosaccharide acceptors derived from Escherichia coli K5 
capsular polysaccharide (Busse 2003).  They demonstrated that EXT1 and EXT1/2 can 
act as HS polymerases without any other auxiliary proteins, while EXT2 incubation 
resulted in the addition of one GlcA residue but no further elongation.  Sismey-Ragatz 
and coworkers achieved in vitro polymerization of HS backbone with Pasteurella 
Multocida enzymes PmHS1 and PmHS2 (Sismey-Ragatz 2007).  Compared with 
PmHS2, PmHS1 was able to produce monodisperse polymers with large molecular mass 
(100-800 kDa) in a stoichiometrically controlled manner.  In contrast, PmHS1 was more 
promiscuous and was able to use many unnatural UDP-sugar analogs as donor substrates.  
Using bacterial glycosyltransferases to synthesize HS backbone becomes more attractive 
because these enzymes are readily expressed. 
An enzymatic approach has been developed to synthesize anticoagulant HS from 
chemically desulfated N-sulfated (CDSNS) heparin (Chen 2005).  In this study, only 
three enzymatic modification steps were required to obtain the HS product with both 
anti-Xa and anti-thrombin activities in milligram scales.  A PAPS regeneration system 
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including arylsulfotransferase IV (AST-IV) was coupled with the sulfotransferase 
reactions catalyzed by 2OST, 6OST or 3OST (figure 18) (Burkart 2000; Chen 2005).  
This regeneration system is essential for practical syntheses of sulfated carbohydrate, 
because despite the high cost of PAPS, the product inhibition caused by PAP, even in low 
micromolar concentrations, is a major obstacle for the enzymatic synthesis with 
sulfotransferases (Lin 1995; Burkart 1999).  With the PAPS regeneration system, the 
byproduct PAP produced from the sulfotransferase reaction is rapidly diminished and 
converted back to PAPS by AST-IV, meanwhile providing a sustained supply of PAPS. 
 
 
 
Figure 18. PAPS regeneration system (Chen 2005) 
 
Arylsulfotransferase IV (AST-IV) uses PNPS as the sulfate donor to replenish the supply of PAPS 
for the sulfotransferase reactions catalyzed by HS sulfotransferases (2OST, 6OST or 3OST).  
The amount of PAP produced from the HS sulfotransferase reactions is also controlled as it is 
consumed by AST-IV to yield fresh PAPS.  
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The synthesis of structurally defined oligosaccharide has also been reported.  
Kuberan and colleagues proposed an enzymatic approach to simplify the synthesis of 
AT-binding pentasaccharide (Kuberan 2003).  The method starts with heparitinase 
I-digested polysaccharide and requires five modification steps by C5-epi, 2OST, 6OSTs, 
glycuronidase and 3OST1.  The resultant pentasaccharide was confirmed by LC-MS and 
gel mobility shift assay.  In addition, Copeland and colleagues recently reported the 
synthesis of a 3-O-sulfated octasaccharide with 3OST3 (Copeland 2008).  The 
octasaccharide blocks the entry and infection of HSV-1 by mimicking the gD-binding 
domain of the entry receptor.  Collectively, these approaches demonstrate it feasible to 
employ current state-of-art enzymatic technologies in hand to assemble bioactive HS 
structures. 
 
Section 6.  Statement of problem 
 
Heparin has been a commonly used anticoagulant drug for decades.  
Low-molecular-weight heparins (LMWHs) have also been approved for clinical use as 
anticoagulant agents with improved bioavailability and pharmacodynamics (Fareed 1998).  
However, as both heparin and LMWH are isolated from animal tissues, their structural 
heterogeneity may lead to multiple in vivo side effects, such as heparin-induced 
thrombocytopenia (HIT) and haemorrhages (Slaughter 1997).  The synthesis of the 
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structure-defined anticoagulant HS is one of the major interests in the field of 
carbohydrate research. 
Despite recent advances, the total chemical synthesis of HS-related structures remains 
challenging and has serious limitations (Linhardt 2007).  For example, the chemical 
synthesis of Arixtra is a daunting task that requires as many as sixty steps with a yield of 
less than 0.5% (Sinaÿ 1984).  With most of the important HS biosynthetic enzymes 
identified and cloned, enzymatic synthesis has become a valuable complement to the 
chemical approach.  Enzymatic synthesis of AT-binding pentasaccharide was first 
accomplished by degrading K5 polysaccharides and utilizing a set of seven HS 
biosynthetic enzymes (Kuberan 2003).  However, in this synthesis, the extent of 
polysaccharide N-deacetylation and digestion is hard to precisely control and only a small 
part of starting materials remained useful for downstream epimerization and O-sulfation.  
In addition, the substrate specificities of HS biosynthetic enzymes become a barrier to 
apply this method to HS oligosaccharides of other size and structures.  In our study, we 
proposed another enzymatic route towards de novo synthesis of structurally defined HS 
oligosaccharides. 
The primary goal of this project is to clone and express the heparosan polymerases in 
bacteria cell lines for the synthesis of HS backbone.  Particularly, E. coli glucuronyl 
transferase KfiA is carefully characterized and tested for its potential in polymerizing 
unnatural sugar residues.  With KfiA and PmHS2 available in large amount, both natural 
(-GlcA-GlcNAc-) and unnatural (-GlcA-GlcNCOCF3-) HS backbones were synthesized 
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step by step from a starting disaccharide derived from E. coli K5 polysaccharide.  
Finally, we synthesized oligosaccharides with defined complete N-sulfation with the HS 
biosynthetic enzyme NST.  We envision that, by driving each downstream enzymatic 
modification step (C5-epi/2OST/6OST/3OST) to completion, these oligosaccharides with 
controlled N-sulfation can be used as the starting substrates to synthesize bioactive HS 
oligosaccharides with defined structures and desired sulfation patterns. 
Collectively, our research will help understand the biosynthesis of HS and simplify 
the syntheses of anticoagulant oligosaccharides.  It may also open the access to the 
enzymatic synthesis of HS oligosaccharides with defined structures which should aid in 
establishing HS structure-function relationships in the future. 
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Chapter II. Materials and methods 
Section 1. Expression and purification of proteins 
Preparation of bacterial genomic DNA (gDNA) 
The bacterial gDNA was prepared using Easy-DNA kit (Invitrogen).  A small overnight 
culture (2 mL) of E. coli K5, K12 or P. multocida type D (American Type Culture 
Collection, ATCC) was harvested and suspended in 200 μL of 1× PBS and mixed well 
with 350 μL of Solution A (Easy-DNA kit, Invitrogen).  After the incubation at 65 oC for 
10 minutes, 150 μL of Solution B (Easy-DNA kit, Invitrogen) was added and the mixture 
was vortexed until the sample was uniformly viscous.  This was followed by adding 500 
μL of chloroform and a vigorous vortex until the sample was homogeneous.  The 
sample was then centrifuged at maximum speed for 15 min to separate phases.  The 
upper aqueous phase was recovered and gDNA was precipitated with 1 mL of 100% 
ethanol (-20 oC).  The gDNA pellet was washed with 500 μL of 80% ethanol (-20 oC) 
and air dried.  The gDNA was resuspended in 100 μL of sterile ddH2O and treated with 
2 μL of RNase (2 mg/mL, Easy-DNA kit, Invitrogen) at 37 oC for 30 min.  The bacterial 
gDNA was then ready for further experiments. 
KfiA 
The KfiA DNA sequence was amplified from E. coli K5 (ATCC) genomic DNA using a 
pair of primers: 5’-ATATATAAGGATCCGATGATTGTTGCAAATATGTC and 
5’-ATAATATACTCGAGCCCTTCCACATTATACAC (the cleavage sites of BamHI and 
XhoI are underlined).  The gene was cloned into the pET21b+ vector (Novagen) to yield 
the C-terminal 6×histidine-tagged protein. 
Expression of KfiA was achieved in BL21 star (DE3) cells (Invitrogen) carrying 
pGro7 plasmid (Takara, Japan) that expresses chaperone proteins GroEL and GroES.  
Briefly, cells containing the plasmids expressing KfiA and GroEL/GroES were grown in 
LB medium supplemented with 50 μg/mL carbenicillin and 35 μg/mL chloramphenicol at 
37 oC.   When A600 reached 0.6, the temperature was decreased to 22 oC, and arabinose 
(1 mg/mL) and isopropyl-β-D-thiogalactopyranoside (IPTG, 1mM) was added to induce 
the expression of chaperone and KfiA, respectively.  The culture was shaken overnight 
at 22 oC.  The bacteria were harvested and lyased by sonication in a buffer containing 25 
mM Tris-HCl (pH=7.5), 500 mM NaCl and 30 mM imidazole.  The protein was purified 
with Ni-Sepharose 6 Fast Flow (0.75 x 10 cm, Amersham), which was eluted with a 
linear gradient of 30 mM to 250 mM of imidazole in 500 mM NaCl and 25 mM Tris-HCl 
(pH 7.5) in 60 mL.  The purity of the resultant protein was analyzed by the precast 10% 
SDS-PAGE (BioRad).  Briefly, samples (10 µl) were diluted with an equal volume of 
sample buffer containing 200 mM Tris-HCl, pH=6.8, and 2% SDS (BioRad).  Gels were 
run at 110V for 1 hour, and then stained with coomassie blue (0.4%) for 30 mins.  Gels 
were destained using 10% acetic acid. 
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GlmU 
The glucosamine-1-phosphate acetyltransferase / N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU) gene was amplified from E. coli K12 (ATCC) genomic DNA 
with the primers: 5’-ATATATAACATATGTTGAATAATGCTATG and 
5’-AATTATAAGGATCCTCACTTTTTCTTTACCGGAC and cloned into pET21b+ 
vector using NdeI and BamHI sites (underlined in the primer sequences) to prepare the 
C-terminal 6 × histidine-tagged GlmU protein.  The expression was carried out in BL21 
star (DE3) cells.  The fusion protein was purified with Ni-Sepharose 6 Fast Flow resins 
as described above. 
 
KfiA/KfiC coexpression 
The full-length KfiA gene with C-his tag was first amplified from the pET21b+ vector 
prepared above with the primers: 5’-ATATTATCCATGGATGATTGTTGCAAATATGTC 
and 5’-ATATTTAATGCGGCCGCTCAGTGGTGGTGGTGGTGGTGC.  It was then 
cloned into the first multiple cloning site of the pCDFDuet-1 vector (Novagen) using 
NcoI and NotI sites (underlined in the primer sequences).  The KfiC DNA sequence was 
amplified from E. coli K5 gDNA using a pair of primers: 
5’-ATATATAAGCGGCCGCAATGAACGCAGAATATATA and 
5’-AATTATAACTCGAGTTGTTCAATTATTCCTGA (the cleavage sites of NotI and 
XhoI are underlined).  The amplified KfiC gene was then cloned into the pET21b+ 
vector (Novagen). 
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The pET21b+ vector carrying KfiC gene was first transformed into the BL21 star 
(DE3) cells (Invitrogen) with chaperone proteins as used in the expression of KfiA.  A 
50 mL culture of this cell was grown in the antibiotics-free LB medium until A600 reached 
0.5.  The cell culture was chilled on ice for 20 min and harvested in sterile tubes.  The 
cell pellet was then resuspended in 5 mL of ice-cold sterile transformation and storage 
solution containing 10% polyethylene glycerol (PEG), 50 mM MgCl2 and 5% dimethyl 
sulfoxide (DMSO) in LB medium.  Aliquots of the cell suspension were placed into 
small tubes by 50 μL each.  A second transformation of the pCDDuet-1 vector carrying 
KfiA gene into this competent cell was performed to yield the BL21 star cells 
coexpressing KfiA, KfiC and chaperone proteins.  The cell culture was prepared and 
harvested similarly as described above.  The C-His tagged KfiA/KfiC complex was 
again purified with Ni-Sepharose 6 Fast Flow (0.75 x 10 cm, Amersham).  
 
PmHS2 
PmHS2 was expressed as an N-terminal fusion to 6×histidine (DeAngelis 2004).  The 
PmHS2 DNA sequence was first amplified from P. multocida type D (P-3881, ATCC) 
genomic DNA using a pair of primers: 
5’-ATGAAGAGAAAAAAAGAGATGACTCAAA and 
5’-TTATAAAAAATAAAAAGGTAAACAGGG without restriction enzyme sites.  The 
PCR product was purified by Qiaquick PCR purification kit (Qiagen) and used as the 
template for a secondary polymerase chain reaction (PCR) with another pair of primers 
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with restriction sites: 5’-ATATATAACATATGATGAAGAGAAAAAAAGAGATGACTC 
and 5’-AATTATAAGGATCCATCATTATAAAAAATAAAAAGGTAAACAGG (the 
cleavage sites of NdeI and BamHI are underlined).  The amplified PmHS2 gene was 
then cloned into the pET15b vector (Novagen) and PmHS2 was expressed in BL21 star 
(DE3) cells (Invitrogen) with chaperone proteins as described above. 
The bacteria were harvested and lyased by sonication in a buffer containing 25 mM 
Tris-HCl (pH=7.5), 500 mM NaCl and 30 mM imidazole.  The protein was purified with 
Ni-Sepharose 6 Fast Flow (0.75 x 10 cm, Amersham), which was eluted with a linear 
gradient of 30 mM to 300 mM of imidazole in 500 mM NaCl and 25 mM Tris-HCl (pH 
7.5) in 60 mL.  The purity of the resultant protein was analyzed by the precast 10% 
SDS-PAGE (BioRad) as described above. 
 
NST 
The expression of NST was reported previously (Sueyoshi 1998).  A plasmid containing 
the sulfotransferase domain of human NDST-1 fused to glutathione S-transferase was 
obtained from Dr. Masahiko Negishi (NIH). The enzyme was expressed, bound to a 
glutathione column (Amersham Pharmacia) for purification, and cleaved from 
glutathione S-transferase using thrombin as described.  
 
C5-epi 
The catalytic domain of human C5-epimerase (E53-N609) was cloned into pMAL-c2X 
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vector (New England Biolabs) using the BamH1 and HindIII sites to generate a 
maltose-binding protein (MBP)-epimerase fusion protein (Muñoz 2006).  The full length 
cDNA of C5-epimerase was a gift from Dr. Rosenberg (Massachusetts Institute of 
Technology).  Expression of C5-epimerase was achieved in Origami-B cells (Novagen) 
carrying pGro7 plasmid (Takara, Japan) which expresses chaperone proteins GroEL and 
GroES.  The bacteria were grown in LB medium supplemented with 2 mg/ml glucose, 
12.5 μg/ml tetracycline, 15 μg/ml kanamycin, 35 μg/ml chloramphenicol, and 50 μg/ml 
carbenicillin at 37 °C.  When the OD 600 nm reached 0.6–0.8, IPTG and L-arabinose 
were added to a final concentration of 0.1 mM and 1 mg/ml, respectively.  The protein 
was purified following the protocol provided by the manufacturer. 
 
2OST, 6OST1 and 6OST3 
As described in our previous publication (Chen 2005), the catalytic domains of 2OST of 
Chinese hamster ovary (Arg51–Asn356) and mouse 6OST1 (His53–Trp401) were cloned 
into the pMAL-c2X vector (New England BioLabs) using the BamHI and HindIII sites to 
generate maltose-binding protein (MBP)-2OST and MBP-6OST1 fusion proteins.  The 
full-length cDNAs of 2OST and 6OST1 were gifts from Dr. Rosenberg (Massachusetts 
Institute of Technology, Cambridge, MA) and Dr. Kimata (Aichi University, Japan), 
respectively.  Expression of 2OST and 6OST1 was achieved in Rosetta-gami B (DE3) 
cells (Novagen) using a standard procedure.  Briefly, cells containing the plasmid 
expressing 2OST or 6OST1 were grown in LB medium supplemented with 2 mg/ml 
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glucose, 15 µg/ml tetracycline, 15 µg/ml kanamycin, 35 µg/ml chloramphenicol, and 50 
µg/ml carbenicillin at 37 °C.  When the A600 reached 0.6–0.8, IPTG (1 mM) was added, 
and the cells were shaken overnight at 22 °C.  The bacteria were harvested, and the 
proteins were purified by following a protocol from the manufacturer (New England 
Biolabs). 
The expression of 6OST3 was also carried out in E. coli (Chen 2007).  In brief, the 
catalytic domain of mouse 6OST3 (Pro121–Pro450) was cloned into a pMalc2x vector 
(New England BioLab) from a mouse brain Quick clone cDNA library (BD Biosciences).  
The expression was carried out in Origami-B cells (Novagen) carrying pGro7 (Takara, 
Japan) plasmid expressing chaperone proteins GroEL and GroES of E. coli. Transformed 
cells were grown in 6 L LB medium supplemented with 2 mg/ml glucose, 12.5 μg/ml 
tetracycline, 15 μg/ml kanamycin, 35 μg/ml chloramphenicol, and 50 μg/ml carbenicillin 
at 37°C.  When the A600 reached 0.4–0.7, IPTG (0.15 mM) and L-arabinose (1 mg/ml) 
were added to induce the expression of 6OST3 and chaperone proteins, respectively.  
The cells were allowed to shake overnight at 22 °C.  Purification was carried out with an 
amylose-agarose (New England BioLab) column by following the protocols provided by 
manufacturer. 
 
3OST1 
As described previously (Edavettal 2004), the catalytic domain of 3OST1 (Gly48-His311) 
was amplified from m3OST1-pcDNA3 with a 5' overhang containing an NdeI site and a 
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3' overhang containing an EcoRI site.  This construct was inserted into the pET28a 
vector (Novagen) using the NdeI and EcoRI restriction sites to produce a His6-tagged 
protein. The resultant plasmid (b3OST1-pET28) was sequenced to confirm the reading 
frame and the lack of mutations within the coding region (University of North Carolina, 
DNA sequencing core facility).  The plasmid, b3OST1-pET28, was transformed into 
BL21(DE3)RIL cells (Stratagene) for the expression of 3OST1.  Cells containing the 
b3OST1-pET28 were grown in 12 2.8-liter Fernbach flasks containing 1 liter of LB 
media with 50 µg/ml kanamycin at 37 °C.  When the A600 reached 0.6-0.8, the 
temperature was lowered to 22 °C for 15 min.  IPTG was then added to a final 
concentration of 200 µM, and the cells were allowed to shake overnight. Cells were 
pelleted and resuspended in 120 ml of sonication buffer, 25 mM Tris, pH 7.5, 500 mM 
NaCl, and 10 mM imidazole.  Cells were disrupted by sonication then spun down. The 
supernatant was applied to nickel nitrilotriacetic acid-agarose resin (Qiagen) in batch and 
washed with sonication buffer.  The resin was loaded onto a column, and the protein was 
eluted with an imidazole gradient from 10 to 250 mM.  The protein was dialyzed then 
concentrated to 16 mg/ml in 20 mM Tris, pH 7.5, 100 mM NaCl, and 4 mM PAP.  A 
total of 28 mg of protein was obtained. 
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Section 2. Preparation of acceptor substrates 
Preparation of heparosan from E. coli K5 
One liter of an overnight culture of E. coli K5 was prepared and spun to recover the 
supernatant only, which was then mixed with equal volume of K5P buffer A containing 
50 mM NaCl and 20 mM NaAcO at pH 4.  After pH was adjusted to 4, the sample was 
loaded onto 10 mL of diethylaminoethyl (DEAE) column preequilibrated with K5P buffer 
A.  The DEAE column was extensively washed with 100 mL of K5P buffer A and then 
eluted with K5P buffer B containing 1 M NaCl and 20 mM NaAcO at pH 4. K5 
polysaccharide was precipitated from eluent after mixed with three volumes of ethanol at 
-20 oC overnight.  The K5 polysaccharide was then dissolved in water and mixed with 
1.7 mL of phenol/chloroform to purify the polysaccharide from the protein impurities.  
K5 polysaccharide was precipitated from the aqueous part again with the addition of three 
volumes of ethanol and incubation at -20 oC overnight. Typically 100 mg of K5 
polysaccharide may be obtained from 1 L of the bacterial culture. 
The concentration of K5 polysaccharide was determined by estimating the amount of 
the resultant disaccharide from a complete digestion of K5 polysaccharide with heparin 
lyase III.  Briefly, K5 polysaccharide (10 µL) was mixed with heparin lyase III (10 µg) 
and incubated at 37 oC for 3 hours.  The resultant disaccharide (ΔUA-GlcNAc) was 
resolved with reverse-phase ion-pairing HPLC (RPIP-HPLC) and quantified by 
comparing the area of a UV232 peak with the same disaccharide standard (Seikagaku) 
with known amount. 
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Preparation of K5 polysaccharide-derived oligosaccharides with various sizes 
Even-numbered oligosaccharides were prepared from a purified capsular polysaccharide 
of E. coli K5, with the structure (GlcA-GlcNAc)n.  The K5 polysaccharide (5.5 mg) 
mixed with 3H-labeled K5 polysaccharide (80,000 cpm) was partially N-deacetylated by 
treating it with 2 M NaOH at 68 °C for 60 min followed by deamination with nitrous acid 
at pH 4.5 (Shaklee 1984).  The resultant oligosaccharides were reduced with sodium 
borohydride to yield a reducing terminal residue of 2, 5-anhydromannitol (anManR).  
The oligosaccharides (GlcA-[GlcNAc-GlcA]n-anManR) were size-fractionated by a 
Bio-Gel P10 (Bio-Rad) column, which was eluted with 20 mM Tris-HCl (pH7.4) and 1 M 
NaCl.  [3H]radioactivity was determined.  Those fractions corresponding to appropriate 
sizes of oligosaccharides ranging from disaccharides to octasaccharides were pooled 
separately (figure 16), dialyzed against double deionized water for 12 hours at 4 oC using 
3,500 Da MWCO membrane (Fisher Scientific) and lyophilized.  The amount of the 
purified oligosaccharides was determined based on the specific [3H]radioactivity of the 
polysaccharide.  Particularly, the disaccharide (GlcA-anManR) was synthesized by 
deamination of the completely N-deacetylated K5 polysaccharide by treating the K5 
polysaccharide with 2 M NaOH at 68 °C for more than 3 hours. 
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Section 3. Preparation of donor substrates 
UDP-GlcN[3H]Ac 
UDP-GlcN[3H]Ac was prepared from sodium [3H]acetate (500 mCi/mMole, MP 
Biomedicals) using GlmU following a method described previously (figure 18) (Leiting 
1998).  The reaction mixture contained Tris-HCl, pH 7.4 (50 mM), sodium [3H]acetate 
(0.2 mM, 0.1 μCi/μL, 500 mCi/mMole), MgCl2 (5 mM), dithiothreitol (DTT) (0.2 mM), 
UTP (2.5 mM), glucosamine-1-phosphate (GlcN-1-P) (2.5 mM), ATP (10 mM), CoASH 
(0.02 mM), acetyl coenzyme A synthetase (0.1 mg/mL, Sigma-Aldrich, St. Louis, MO), 
recombinant GlmU (0.4 mg/mL) and inorganic pyrophosphatase (0.01 U/μL, 
Sigma-Aldrich, St. Louis, MO).  The reaction was incubated at 30 oC overnight with 
mild agitation.  The yield of UDP-GlcN[3H]Ac was monitored with RPIP-HPLC as 
demonstrated by a [3H]-labeled peak coeluted with unlabeled UDP-GlcNAc standard 
(Sigma) that has absorbance at 256 nm.  The specific [3H]radioactivity of 
UDP-GlcN[3H]Ac was estimated to be 172 mCi/mMole.  UDP-[14C]GlcA (100 μM, 20 
μCi/mL, 200 mCi/mMole) was obtained from PerkinElmer Life and Analytic Sciences 
(Boston, MA).  
 
UDP-GlcNCOCF3
UDP-GlcNCOCF3 was synthesized in a chemoenzymatic way as shown in figure 26.  
The reaction precursor GlcN-1-phosphate was bought from Sigma-Aldrich.  11 mg of 
GlcN-1-phosphate was dissolved in 200 μL of anhydrous methanol and mixed with 60 μL 
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of (C2H5)3N and 130 μL of CF3CO-SC2H5.  The reaction was incubated at room 
temperature for 24 hours and dried to recover the resultant GlcNCOCF3-1-phosphate.  
About 0.5 mg of GlcNCOCF3-1-phosphate was incubated with Tris-HCl 7.4 (46 μM), 
MgCl2 (5 mM), dithiothreitol (DTT, 200 μM), UTP (2.5 mM), recombinant GlmU (1.5 
mg/mL), and inorganic pyrophosphatase (0.012 U/μL) in a reaction of 200 μL.  The 
product was purified by HPLC using a home-made amino column packed with 
YMC*GEL Amino 12 nm S-15μm (YMC).  The column was eluted with a linear 
gradient of 0 mM to 1000 mM of KH2PO4 in 60 min at a flow rate of 1 mL/min.  The 
synthesized UDP-GlcNCOCF3 was eluted with 500 mM KH2PO4.  
 
Section 4.  Determination of the binding of KfiA to various donor substrates with 
Isothermal Titration Calorimetry (ITC) 
 
ITC was performed on a MicroCal VP-ITC (MicroCal, Northampton, MA) (Edavettal 
2004).  Solutions were degassed under vacuum before use.  Purified KfiA was dialyzed 
against a buffer containing 25 mM Tris, 250 mM NaCl, 10 mM MnCl2, pH 7.5 (Tris 
buffer) at 4 °C overnight.  Experiments were conducted in the Tris buffer using 50 µM 
KfiA (1.35 mg/ml).  Titrations were performed by injecting 5 µL of 1.5 mM UDP and 
UDP-sugars (UDP-GlcNAc, UDP-GlcA, UDP-glucose and UDP-GalNAc) in 25 mM Tris 
buffer (250 mM NaCl, 10 mM MnCl2, pH 7.5).  The experimental data was analyzed 
with Origin Version 7 which was preinstalled in MicroCal VP-ITC. 
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Section 5. Glycosyltransferase assays on KfiA, KfiA/KfiC and PmHS2 
KfiA 
N-acetyl D-glucosaminyl transferase assays were carried out with purified KfiA and 
size-defined oligosaccharide acceptors.  The assay was designed to determine the 
incorporation of a GlcN[3H]Ac residue to the defined oligosaccharide substrates.  The 
reaction mixture contained 15,000 cpm of UDP-GlcN[3H]Ac, 100 µg/mL KfiA, 1% 
Triton X-100, 25 mM Tris-HCl 7.2, 10 mM MnCl2, and the appropriate oligosaccharide 
acceptor (Hodson 2000).  Each reaction sample was mixed with 100 µL of 330 mM 
tetrabutylammonium phosphate monobasic (Fluka) and subject to the analysis by the 
reverse-phase ion-pairing HPLC (RPIP-HPLC).  A Beckman Coulter System Gold 
Microbore HPLC system with 32 Karat software (Beckman Coulter, Fullerton, CA) was 
used to perform all HPLC assays.  A C18-column (0.46 × 25 cm) (Vydac) was used to 
resolve the resultant [3H]oligosaccharides and preequilibrated in a buffer containing 
38 mM ammonium phosphate monobasic, 2 mM phosphoric acid, and 1 mM 
tetrabutylammonium phosphate monobasic (Fluka).  The column was isocratically 
eluted at 0.5 mL/min with 0% acetonitrile at 0 min, 7.5% acetonitrile at 10 min, 15% 
acetonitrile at 25 min, and 30% acetonitrile at 40 min, and 50% acetonitrile at 50 min.  
The eluent was monitored by an on-line radioactive detector (β-ram, INUS) for 
measuring radioactivity and an on-line System Gold 166 detector (Beckman Coulter, 
Fullerton, CA) for measuring UV absorbance at the wavelength of 260 nM. 
The enzyme kinetics of the N-acetyl D-glucosaminyl transferase activity of the 
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purified KfiA was evaluated by monitoring the incorporation of GlcN[3H]Ac.  Reactions 
were carried out at oligosaccharide acceptor substrate concentration varying from 3 µM 
to 800 µM in a buffer of enzymatic assay described above.  To measure the Km and 
Kcat/Km of UDP-GlcNAc, we conducted the reactions with the disaccharide (700 µM) as 
an acceptor substrate.  To study the influence of KfiC on KfiA kinetics, enzymatic 
reactions towards disaccharide substrates were also prepared with KfiA at 2.7 µM and 
KfiC at 1.5 µM.  Because the reaction rate remained constant up to 6 min, the average 
reaction rate of the first 2 min represented the initial velocity.  The reactions were 
incubated at 37 oC for 2 min and quenched by heating to 100 oC.  The products were 
resolved by a C18-column (0.46 × 25 cm) (Vydac) under the RPIP-HPLC elution 
condition (Liu 1999).  Briefly, the column was isocratically eluted with different 
concentrations of acetonitrile depending on the size of oligosaccharide product in a 
solution containing 38 mM ammonium phosphate monobasic, 2 mM phosphoric acid, and 
1 mM tetrabutylammonium phosphate monobasic (Fluka) at a flow rate of 0.5 ml/min.  
For the trisaccharide product, no acetonitrile was present in the elution buffer; for penta- 
and hepta-saccharide, 7.5% acetonitrile was present in the elution buffer; for the 
nonasaccharide, 15% acetonitrile was present in the mobile phase.  The eluent was 
monitored by an on-line radioactive detector (β-ram, INUS) for measuring 
[3H]radioactivity. 
KfiA/KfiC 
The glucuronyl transferase assay on KfiA/KfiC complex was carried out with KfiA/KfiC 
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and a [3H]-labeled heptasaccharide acceptor prepared from a KfiA reaction.  The assay 
was designed to monitor the incorporation of a GlcA residue to [3H]-labeled 
heptasaccharide and the resultant [3H]-labeled octasaccharide with RPIP-HPLC using the 
same HPLC method as described above.  The reaction mixture contained 15,000 cpm of 
[3H]-heptasaccharide, 50 µM UDP-GlcA, 100 µg/mL KfiA/KfiC, 1% Triton X-100, 25 
mM Tris-HCl 7.2, 10 mM MgCl2 and 10 mM MnCl2 (Hodson 2000). 
PmHS2 
The glycosyltransferase activities of PmHS2 were tested in a different fashion.  The 
reactions contained 15,000 cpm of UDP-GlcN[3H]Ac (for N-acetyl D-glucosaminyl 
transferase test) or UDP-[14C]GlcA (for glucuronyl transferase test), 100 µg/mL PmHS2, 
1% Triton X-100, 25 mM Tris-HCl 7.2, 10 mM MnCl2, and an even-numbered 
oligosaccharide acceptor with a GlcA at the non-reducing end (such as a disaccharide, for 
N-acetyl D-glucosaminyl transferase test) or an odd-numbered oligosaccharide with a 
GlcNAc at the non-reducing end (such as a trisaccharide, for glucuronyl transferase test).  
The resultant [3H]-labeled trisaccharide or [14C]-labeled tetrasaccharide were determined 
on a Bio-Gel P10 (Bio-Rad) column, which was eluted with 20 mM Tris-HCl (pH7.4) 
and 1 M NaCl.   
 
Section 6. Synthesis and purification of heparan sulfate backbones 
 
Disaccharides were prepared from the complete deacetylation and degradation of K5 
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polysaccharides as described above and were used as the starting materials in the de novo 
synthesis of HS backbones.  A small scale radioactive KfiA reaction with disaccharide 
as acceptor and UDP-GlcN[3H]Ac as donor was incubated at 37 oC for 1 hour and then 
loaded onto a Bio-Gel P10 column.  The P10 column was used to purify the synthesized 
oligosaccharides based on their size.  The elution time/position of the [3H]trisaccharide 
on the P10 column was recorded as a standard.  A large scale KfiA reaction containing 
4.5 μmole (1.52 mg) of disaccharide as acceptor in excess and 3.9 μmole (2.58 mg) of 
UDP-GlcNCOCF3 as donor was also prepared in a buffer with 25 mM Tris-HCl (pH 7.2), 
10 mM MnCl2, 10 mM MgCl2 in the presence of KfiA (0.1 mg/mL).  The reaction 
product was loaded onto the P10 column where the elution fractions corresponding to the 
trisaccharide standard were pooled, dialyzed against double deionized water for four 
hours (MWCO 1000, Spectrum), and dried. 
The purified trisaccharide was used as donor for the next radioactivity-free PmHS2 
reaction containing 2.87 μmole (1.71 mg) of trisaccharide, 3 μmole (1.74 mg) of 
UDP-GlcA in excess, 25 mM Tris-HCl (pH 7.2), 10 mM MnCl2, 10 mM MgCl2 and 0.1 
mg/mL PmHS2.  The trisaccharide was also used in a small scale radioactive PmHS2 
reaction with UDP-[14C]GlcA as donor.  The resultant [14C]-tetrasaccharide was again 
resolved on a Bio-Gel P10 column and its elution time/position was recorded as the 
standard to blindly purify radioactivity-free tetrasaccharide from the large scale cold 
synthesis. 
Additional rounds of KfiA and PmHS reactions were repeated until the synthesized 
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oligosaccharides reached the size we desired.  The enzymatic synthesis of natural HS 
backbones containing GlcNAc was carried out in the same way as mentioned above. 
 
Section 7. Mass spectrometry 
 
Electrospray ionization mass spectrometry (ESI-MS) 
The purified oligosaccharides were further desalted by dialysis against doubled deionized 
water.  The samples were then dried with a vacuum concentrator, reconstituted in 
doubled deionized water (50 μM, 200 μL) and introduced by direct infusion (10 μL/min) 
to ESI-MS (Agilent 1100 MSD-Trap at the Mass Spectroscopy Core in the UNC School 
of Pharmacy).  Experiments were performed at negative ionization mode with a source 
temperature of 350 oC.  Nitrogen was used as a drying (5 liters/min) and nebulizing gas 
(15 p.s.i.). 
 
Liquid chromatography-mass spectrometry (LC-MS) 
LC-MS analyses were performed on Agilent 1100 LC/MSD instrument (Agilent 
Technologies, Inc. Wilmington, DE, U.S.A.) equipped with an ion trap, binary pump and 
a UV detector at the Rensselaer Polytechnic Institute.  The column was a 5 μm Agilent 
Zorbax SB-C18 (0.5 × 250 mm) from Agilent Technologies. Eluent A was 
water/acetonitrile (85:15), v/v and eluent B was water/acetonitrile (35:65) v/v.  Both 
eluents contained 12 mM tributylamine (TBA) and 38 mM NH4OAc and their pH was 
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adjusted to 6.5 with HAcO.  The sample was diluted 10-fold with water and 1 μl of the 
resulting analyte was injected by auto-sampler.  A gradient of 0% B for 15 min, and 
0-100% B over 85 min. was used at a flow rate of 10 μl/min.  Mass spectra were 
obtained using an Agilent 1100 series Classic G2445D LC/MSD trap (Agilent 
Technologies, Inc. Wilmington, DE, U.S.A.).  The electrospray interface was set in 
negative ionization mode with the skimmer potential -40.0 V, capillary exit -120 .5 V and 
a source temperature of 325 °C to obtain maximum abundance of the ions in a full scan 
spectra (150–1500 Da, 10 full scans/s).  Nitrogen was used as a drying (5 liters/min) and 
nebulizing gas (20 p.s.i.).  Auto tandem mass spectrometry (MS/MS) was turned on in 
these experiments using an estimated cycle time of 0.07 min.  Total ion chromatograms 
(TIC) and mass spectra were processed using Data Analysis 2.0 (Bruker software). 
 
Section 8.  Modifications of heparan sulfate backbones 
 
N-deacetylation (removal of N-trifluoroacetyl group) 
200 μg of the purified N-trifluoroacetyl oligosaccharides were dried and resuspended in a 
solution of 200 μL containing methanol, ddH2O and triethylamine (v/v/v=2:2:1).  The 
reaction was incubated at room temperature for 20 hours.  The sample was then dried by 
a vacuum concentrator (Contrivap Concentrator, Labconco) and reconstituted in ddH2O 
to recover the N-deacetylated oligosaccharides. 
 
 66
Partial and complete N-sulfation of [3H]heptasaccharide by NST 
PAPS was directly used as the sulfate donor in a 50-µL NST reaction which contained 16 
µM [3H]heptasaccharide, 50 mM MES (pH 7), 0.1% Triton X-100, 10 mM MnCl2, 500 
µM PAPS and 0.36 mg/mL NST.  The reaction was incubated at 37 oC and sampled at 2 
hours and overnight.  3 µL of each sample was analyzed with RPIP-HPLC which was 
preequilibrated with buffer A (38 mM ammonium phosphate monobasic, 2 mM 
phosphoric acid and 1 mM tetrabutylammonium) and eluted at 0.5 mL/min.  The 
isocratic elution started at 100% of buffer A (or 0% of buffer B) (38 mM ammonium 
phosphate monobasic, 2 mM phosphoric acid, 1 mM tetrabutylammonium, and 50% 
acetonitrile), switched to 30% of buffer B at 10 min, 60% at 25 min, and finally changed 
to 100% of buffer B at 40 min.  The monosulfated and disulfted heptasaccharide were 
eluted at 27 min and 35 min, respectively. 
Sulfotransferase reactions coupled with a PAPS regeneration system 
A PAPS regeneration system was used to scale up the sulfation reactions (figure 18) 
(Burkart 2000).  Briefly, a 1-mL regeneration reaction consisted of 50 mM MES 
(2-(N-morpholino)ethanesulfonic acid) (pH 7), 40 µM PAP, 1 mM paranitrophenol sulfate 
(PNPS), 50 µl purified arylsulfotransferase-IV (AST-IV), and 10 µg of the purified HS 
sulfotransferase (NST, 2OST, 6OST1, 6OST3 or 3OST1) was incubated at room 
temperature for 15 mins.  The coupling efficiency was monitored by measuring the 
concentration of PNP at A410.  Once equilibrium was reached, 50 µg of the 
oligosaccharide substrate was added and the mixture was rotated at room temperature 
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overnight. 
 
Purification of the fully N-sulfated [3H]oligosaccharides with HPLC 
The synthesized NS-[3H]heptasaccharide was purified with a C-18 column (Vydac).  
The same RPIP-HPLC method was used as for analysis of the partially N-sulfated 
[3H]heptasaccharide mentioned above, except that 35% of buffer B was applied at 10 min.  
NS-[3H]heptasaccharide was eluted at around 30% acetonitrile (60% buffer B).  
The synthesized NS-[3H]undecasaccharide was purified with a polyamine II column 
(YMC), which was eluted with a linear gradient of 0 mM to 1000 mM KH2PO4 in 60 min 
at 0.5 mL/min on HPLC.  NS-[3H]undecasaccharide was eluted at 680 mM KH2PO4.  
 
Nitrous acid degradation of the fully N-sulfated [3H]oligosaccharides 
The extent of N-sulfation of the synthesized NS-[3H]heptasaccharide and 
NS-[3H]undecasaccharide was examined by high pH and low pH nitrous acid 
degradation. 
In the nitrous acid degradation at high pH (pH 4.5), about 150 ng (10000 cpm) of the 
[3H]-labeled NS-oligosaccharide was dried and redissolved in 100 µL of the mixture of 
0.5 M H2SO4 and 5.5 M NaNO2 (v/v=2:5).  The sample was incubated on ice for 30 min 
and occasionally vortexed.  The degradation was stopped by adding 60 µL of the 
solution containing 1 M Na2CO3, 1 M NaHCO3 and ddH2O (v/v/v=3:5:5).  The sample 
was then mixed with 0.5 µL of 5% phenol red and loaded onto a Bio-Gel P10 column for 
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analysis. 
In the nitrous acid degradation at low pH (pH 1.5), about 150 ng (10000 cpm) of the 
[3H]-labeled NS-oligosaccharide was dried and reconstituted in 20 µL of the ddH2O.  20 
µL of 0.5 M H2SO4 and 20 µL of 0.5 M Ba(NO2)2 was mixed and spun.  The 
supernatant was added to the oligosaccharide sample, which was then incubated on ice 
for 30 min with occasional vortex.  A 20-µL solution containing 1 M 1 M Na2CO3 and 1 
M NaHCO3 (v/v=7:3) was added to quench the degradation.  The sample was then 
mixed with 0.5 µL of 5% phenol red and loaded onto a P10 column for analysis. 
 
Modification of the N-sulfated octasaccharide in a one-pot reaction 
The N-sulfated octasaccharide backbone was modified by HS biosynthetic enzymes in a 
one-pot 100-µL reaction.  Briefly, 200 ng of the N-sulfated octasaccharide was first 
treated with C5-epi (0.1 mg/mL) in the presence of 25 mM MES (pH 7), 0.5% Triton 
X-100, and 1 mM CaCl2 at 37 oC for 1 hour.  The other HS biosynthetic enzymes were 
then added, including 2OST (0.4 mg/mL), 6OST1 (0.3 mg/mL), 6OST3 (0.5 mg/mL), 
3OST1 (0.1 mg/mL), along with PAP[35S] (25 µM, 19000 cpm/µL).  A negative control 
reaction was also prepared with every enzyme included except for 3OST1.  Both 
reactions were incubated at 37 oC overnight and boiled for 1 min to stop the reaction.   
 
Determination of the binding of the modified octasaccharides to antithrombin (AT) 
Both the 3-O-sulfated octasaccharide and the modified octasaccharide without 
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3-O-sulfation were tested for AT-binding with a concanavalin A (ConA)-based assay.   
Approximately 260 ng of [35S]-labeled compound were incubated with 5 µg of human 
AT (Cutter Biological) in 50 µl of binding buffer containing 20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1 mM Mn2+, 1 mM Mg2+, 1 mM Ca2+, 15 µM dextran sulfate, 0.003% 
Triton X-100 for 1 hour at room temperature.  Concanavalin A-Sepharose (Sigma; 50 µl 
of 1:1 slurry) was then added, and the reaction was shaken at room temperature for 4 h. 
The beads were then washed by 3 × 1 ml of binding buffer, and the bound polysaccharide 
was eluted with a buffer containing 20 mM Tris-HCl (pH 7.5) and 1 M NaCl. 
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Chapter III. Determination of the substrate specificities of 
N-acetyl-D-glucosaminyl transferase KfiA 
Section 1. Introduction 
E. coli K5 capsular polysaccharide consists of GlcNAc and GlcA repeating disaccharide, 
an analogue of unsulfated and unepimerized HS backbone (Vann 1981).  Using the 
enzymes involved in the biosynthesis of K5 polysaccharide offers an alternative approach 
to prepare HS backbones (figure 9).  Previous studies (Hodson 2000) have indicated that 
the biosynthesis of K5 polysaccharide requires an N-acetyl-D-glucosaminyl transferase, 
KfiA.  This enzyme, together with D-glucuronyl transferase KfiC (Griffiths 1998), 
alternatively incorporates GlcNAc and GlcA residues, from UDP-GlcNAc and 
UDP-GlcA to the nonreducing ends of the oligo- or polysaccharides (figure 9).  
Although KfiA is of interest to synthesize HS backbones, the substrate specificity of this 
enzyme is still poorly understood.  The lack of information about its biochemical 
features is primarily due to the unavailability of the purified enzyme.  In this chapter, an 
efficient way to prepare purified KfiA in multi-milligram quantities is described.  
Substrate specificities of KfiA were also characterized.  The results from this study 
demonstrated the possibility of the synthesis of HS backbone from a disaccharide 
structure using KfiA.   
Section 2. Expression and purification of KfiA 
 
KfiA was previously identified as carrying N-acetyl glucosaminyl transferase activity 
responsible for the synthesis of capsular polysaccharide in E. coli K5 using a site-directed 
mutagenesis approach in a cell based assay (Hodson 2000).  However, the biochemical 
character of this enzyme has not been fully elucidated because of the unavailability of 
purified enzyme.  The potential application of KfiA in synthesizing defined size HS 
backbone structures prompted us to investigate its donor and acceptor substrate 
specificities.  The full length KfiA gene was cloned from E. coli K5 genomic DNA and 
expressed in a format of C-terminal 6×His fusion protein as described under “Materials 
and Methods”.  Recombinant KfiA was purified by affinity chromatography using a 
nickel column.   The purified KfiA predominantly migrated as one major band at ~27 
KDa on a 10% SDS-PAGE (figure 19), which is nearly identical to the calculated 
molecular weight of KfiA (27.3 KDa).  We estimated that the purity of KfiA was greater 
than 90%.  Approximately 10 mg of purified KfiA was obtained from 1 liter of bacterial 
culture. 
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Figure 19. The purified KfiA on SDS-PAGE 
 
Affinity chromatography purified KfiA protein was resolved on precasted 10% SDS-PAGE.  The 
gel was stained with coomassie blue.  Migration positions of molecular markers (from BioRad) 
are indicated.  The apparent mass was approximately 27 KDa. The predicted molecular mass of 
KfiA is 27.3 KDa. 
 
 
 
 
 
 
 
 73
Section 3. Preparation of even-numbered oligosaccharide acceptors 
 
To study the size specificity of the acceptor for KfiA, even-numbered oligosaccharides 
were prepared from K5 polysaccharide by partial N-deacetylation followed by 
deaminative cleavage.  To monitor the polysaccharide during the purification, unlabeled 
K5 polysaccharide was mixed with [3H]metabolically labeled K5 polysaccharide.  The 
polysaccharide was deacetylated under a basic condition, and the resultant polysaccharide 
was subject to nitrous acid (pH 4.5) degradation.  The oligosaccharide products with the 
structures of GlcA-[GlcNAc-GlcA]n-anManR were resolved on Bio-Gel P10 column 
based on the size of the oligosaccharides, such as di-, tetra-, hexasaccharide, etc (figure 
20).   
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Figure 20. Fractionation of partially depolymerized K5 polysaccharide on P10 column. 
 
K5 polysaccharide was partially digested as described under “Materials and Methods”. The 
products were fractionated (9 drops/fraction) by gel chromatography on a Bio-Gel P10 column 
eluted with 20 mM Tris-HCl 7.4 and 1 M NaCl.  The resultant oligosaccharides (from 
disaccharide to octasaccharide) were desalted and reconstituted in double deionized water for 
mass spectrometry analysis and enzymatic assays. 
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Due to the resolution of the BioGel P-10 column, we were limited to obtaining up to 
octasaccharide with sufficient purity (>90%).  The purified oligosaccharides were also 
subjected to the analysis of electrospray ionization mass spectrometry (ESI-MS) to 
confirm the molecular weight.  The MS spectra of those analyzed oligosaccharides are 
shown in figure 21.  Furthermore, we did not observe the oligosaccharide with different 
sizes in a given sample, suggesting that the purified oligosaccharides are sufficiently pure 
(with purity >90%) for the kinetic studies as described below.  The molecular weights of 
the purified oligosaccharides were consistent with the anticipated size of the 
oligosaccharide (table 3). 
 
 
Sample Formulaa Calculated Mr (Da) 
Detected Mr 
(Da) 
Detected molecular ion 
(m/z) 
disaccharide C12 H20O11 340.28 340.01 [M-H]- 339.0 
tetrasaccharide C26 H41O22N 719.60 719.25±0.05b
[M-2H]2- 358.6 
[M-2H+Na]- 740.3 
hexasaccharide C40 H62O33N2 1098.91 1098.84±0.40b
[M-3H+Na]2- 559.6 
[M-3H+2Na]- 1141.4 
octasaccharide C54 H83O44N3 1478.23 1477.46±0.01b
[M-4H+2Na]2- 759.7 
[M-4H+3Na]- 1542.4 
 
Table 3. Molecular weight (Mr) of the purified oligosaccharides determined by ESI-MS 
 
a. Molecular masses were calculated by Molecular Weight Calculator 
(http://ncrr.pnl.gov/software/). 
b. The value is the average ± range of the detected molecular ions. 
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Figure 21. Electrospray ionization mass spectra of purified oligosaccharides. 
 
Panel A, B, C, and D shows the ESI-MS spectrum of the disaccharide, tetrasaccharide, 
hexasaccharide, and octasaccharide, respectively.  The samples were introduced by direct 
infusion (10 μL/min) to ESI-MS.  The expected anions are indicated. 
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Section 4. Synthesis of [3H]-labeled UDP-N-acetylglucosamine (UDP-GlcN[3H]Ac) 
 
Since radio-labeled UDP-sugars are prohibitively expensive and the stability of 
commercial UDP-GlcN[3H]Ac was not reliable, I synthesized UDP-GlcN[3H]Ac using a 
method modified from the previous publication (Leiting 1998) (figure 22). [3H]Acetate 
was used to produce [3H]acetyl CoA by acetyl coenzyme A synthetase. Bifunctional 
enzyme GlmU was cloned from E. coli genome and expressed in bacteria to synthesize 
GlcN[3H]Ac-1-phosphate and finally produce UDP-GlcN[3H]Ac. 
 
 
 
 
Figure 22. Enzymatic synthesis of UDP-GlcN[3H]Ac (Leiting 1998) 
 
E1, acetyl coenzyme A synthetase 
E2, inorganic pyrophosphatase 
 
 
 
 78
Section 5. Determination of the enzymatic activity of KfiA 
 
The activity of KfiA was determined using a purified tetrasaccharide as an acceptor, and 
the product was resolved on RPIP-HPLC.  A [3H]-labeled peak eluted at 18 min was 
observed (solid line, figure 23A), while this [3H]-labeled peak was absent in the control 
(without KfiA enzyme, dotted line, figure 23A), suggesting that a 3H-labeled 
pentasaccharide was generated due to the action of KfiA.  It should be noted that more 
than 90% of the UDP-GlcN[3H]Ac had been converted to the 3H-labeled pentasaccharide 
within 30 min of initiating the reaction under the standard assay condition, demonstrating 
that recombinant KfiA was highly active.  This pentasaccharide was purified by 
RPIP-HPLC, and its molecular mass was determined to be 922.6 Da ([M-2H]2- = 460.3, 
Mr = 922.6 Da) by ESI-MS (figure 23B), which is almost identical to the calculated 
molecular mass of the anticipated pentasaccharide (922.8 Da). 
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Figure 23. RPIP-HPLC chromatograms and ESI-MS spectrum of KfiA-modified 
tetrasaccharide acceptor. 
 
Panel A shows the RPIP-HPLC chromatograms of KfiA-modified tetrasaccharide.  
UDP-GlcN[3H]Ac was incubated with tetrasaccharide acceptors as described in “Materials and 
Methods” with (solid line) or without KfiA (dotted line).  The reaction products were separated 
on RPIP-HPLC eluted with 50% acetonitrile in a solution containing 38 mM ammonium 
phosphate monobasic, 2 mM phosphoric acid, and 1 mM tetrabutylammonium phosphate 
monobasic at a flow rate of 0.5 ml/min. 
Panel B shows the ESI-MS spectrum of KfiA-modified product.  The pentasaccharide was 
prepared by incubating the tetrasaccharide, KfiA and unlabeled UDP-GlcNAc.  The product was 
purified by RPIP-HPLC, knowing the eluted position of [3H]pentasaccharide.  The resultant 
pentasaccharide was dialyzed and analyzed by ESI-MS.  A doubly charged anion (m/z = 460.3), 
corresponding to the pentasaccharide molecule, was detected.  Thus, the determined Mr was 
922.6 (Da), which is consistent with the calculated Mr of the pentasaccharide (922.8 Da). 
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Section 6. KfiA transfers N-acetyl glucosamine to the acceptors with different sizes 
 
The requirement for the size of the substrate for KfiA was investigated by incubating the 
enzyme and the acceptor substrates with various sizes in the presence of 
UDP-GlcN[3H]Ac, and the [3H]-labeled products were analyzed by RPIP-HPLC (figure 
24).  It shows that KfiA is capable of transferring the GlcNAc residue to the acceptor as 
small as disaccharide. 
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Figure 24. RPIP-HPLC chromograms of KfiA catalyzed N-acetyl glucosaminyl reactions 
with different sizes of the acceptor substrate. 
 
Various oligosaccharide substrates were incubated with purified KfiA and UDP-GlcN[3H]Ac.  
The reaction was terminated by heating at 100oC for 2 min.  The resultant [3H]oligosaccharides 
were resolved by RPIP-HPLC eluted with different concentrations of acetonitrile as described in 
“Materials and Methods”.  Panel A, B, C, and D shows the chromatogram of using disaccharide, 
tetrasaccharide, hexasaccharide and octasaccharide substrate, respectively. 
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To further quantify the susceptibility of the acceptors to KfiA modification, we 
determined Km and Kcat/Km of KfiA towards various acceptors.  The amount of the 
3H-labeled oligosaccharide product was determined by integrating the corresponding 
[3H]-peak from RPIP-HPLC.  As shown in table 4, the binding affinities (as estimated 
by Km) of various acceptors to KfiA are similar (between 256 and 674 µM), while the 
catalytic efficiency of KfiA (Kcat/Km) moderately increases as the acceptor elongates 
(from 1.2 to 4.1).  This suggested that elevated GlcNAc transfer efficiency could occur 
as the saccharide chain is elongated.  We attempted to determine the Km and Kcat/Km 
values of KfiA for K5 polysaccharide, but failed to obtain a consistent value partly 
because the impurities in the polysaccharide substrate interfered with the enzymatic 
reaction.  We also examined the potential effect of purified recombinant KfiC on the Km 
and Kcat/Km of KfiA towards a disaccharide substrate.  We found that the Km and Kcat/Km 
for KfiA (in the presence of 1.5 µM of KfiC) is 315 µM and 1.4 (M-1S-1) respectively, 
while the Km for Kcat/Km for KfiA (in the absence of KfiC) is 256 µM and 1.2 (M-1S-1) 
respectively.  This observation suggests that purified KfiC has no significant effect on 
the kinetic character of KfiA in this system.   
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Substrates Km (μM) Kcat/Km (M-1S-1) R2a
UDP-GlcNAcb 94 3.7 0.9935 
Disaccharidec 256 1.2 0.9968 
Tetrasaccharide 324 1.2 0.9976 
Hexasaccharide 674 2.7 0.9959 
Octasaccharide 254 4.1 0.9931 
 
Table 4. Km and Kcat/Km values of KfiA towards different acceptors 
 
a. R2 represents the coefficient determination for the data to fit Michaelis-Menten equation.  
b. Disaccharide was used as an acceptor substrate as explained under “Materials and Methods”. 
c. The concentration of UDP-GlcN[3H]Ac used in the assays was 1270 μM. 
 
Section 7. Donor specificities of KfiA 
 
It is believed that KfiA utilizes UDP-GlcNAc as a donor substrate in vivo.  We further 
studied the donor specificity of KfiA.  Isothermal Titration Calorimetry (ITC) was 
employed to measure the binding affinities between KfiA and different UDP-sugars (table 
5).  As the natural donor of KfiA, the dissociation constant (Kd) for UDP-GlcNAc was 
determined to be 62 µM, while we could not detect bindings between KfiA and 
UDP-GlcA, UDP-glucose or UDP-N-acetyl-galactosamine (GalNAc).  This suggested 
that KfiA recognizes specific functional groups of GlcNAc residue, including the 
N-acetyl group (the difference of glucose and GlcNAc is at the C2 position) and the 
orientation of the hydroxyl group (the difference between galactosamine and glucosamine 
is at the C4 position).  UDP demonstrated a comparable binding affinity (27 µM) to that 
of UDP-GlcNAc, which implies that UDP might exhibit product inhibition of KfiA.  
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Indeed, the IC50 of UDP on the N-acetyl D-glucosaminyl transferase activity of KfiA was 
measured to be 150 µM. The observation of the binding of UDP to KfiA, although 
somewhat surprising, is consistent with the previous studies on 
UDP-N-acetylhexosaminyltransferase, EXTL2 (Saobhany 2005).  The Km of KfiA 
towards UDP-GlcNAc was determined to be 94 µM, which is very similar to the 
dissociation constant (Kd) (62 µM). 
 
Donors Structures of donor substrates Kd (μM) Na
UDP 
 
27 1.25 
UDP-GlcNAc 
 
62 1.04 
UDP-GlcA 
 
NDb NDb
UDP-Glucose 
 
NDb NDb
UDP-GalNAc 
 
NDb NDb
 
Table 5. Binding affinities of various UDP-sugars 
 
a, binding stoichiometry  
b, not detected 
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Section 8. Conclusion and discussion 
 
Previous reports demonstrated that at least four proteins are involved in the synthesis of 
K5 polysaccharide, including KfiA, KfiB, KfiC and KfiD (Griffiths 1998) (Hodson 2000).  
Although KfiA has been overexpressed in E. coli (Hodson 2000), the purified form has 
not been reported.  Furthermore, the donor and acceptor substrate specificity of KfiA 
with purified protein has not been extensively studied.  In this chapter, the successful 
expression and purification of KfiA in a multi-milligram scale was achieved with E. coli 
coexpressing chaperone proteins.  The access of highly purified KfiA allowed us to 
conduct substrate specificities using established approaches.   
The substrate specificities of KfiA are unique for its application in the synthesis of HS 
backbone.  Incubation of KfiA with oligosaccharide acceptors of various sizes all 
yielded extended oligosaccharide products.  Our results suggested that KfiA can be 
employed in the de novo synthesis of HS backbones starting from as short as disaccharide, 
provided that a disaccharide is readily available from complete depolymerization of K5 
polysaccharide with nitrous acid.  It is interesting to note that KfiA activity is inhibited 
by UDP.  Whether UDP competes with UDP-GlcNAc in the same binding pocket on 
KfiA and regulate the extent of the polymerization of capsular polysaccharide of in vivo 
remains to be investigated.  We do not rule out the possibility that KfiA transfers a 
GlcNAc residue towards other glycosaminoglycan substrates, including hyaluronic acid 
oligosaccharides, due to the unavailability of those substrates.  Clearly, an efficient 
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expression of KfiA and detailed substrate specificity information will serve as an 
important tool to conduct in vitro enzymatic synthesis of HS and to probe the biosynthetic 
mechanism of HS.  
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Chapter IV. De novo synthesis of heparan sulfate 
oligosaccharide backbones 
Section 1. Introduction 
Structurally defined HS can be used to probe the functions of HS in a given biological 
system. The availability of structurally defined HS oligosaccharides is a major challenge 
to study the structure-function relationship of HS.  Although the chemical synthesis has 
proven to be the most efficient way to prepare the structurally defined HS 
oligosaccharides in sizes smaller than hexasaccharides (Avci 2003), it has become clear 
that chemical synthesis alone is currently incapable of generating majority of larger 
oligosaccharide structures. 
Our laboratory and others began to explore the use of a collection of HS biosynthetic 
enzymes to synthesize HS with desired biological activities (Kuberan 2003; Kuberan 
2003; Chen 2005; Lindahl 2005; Muñoz 2006).  However, it is unclear that the 
enzymatic approach offers the HS polysaccharide products with defined sequences in part 
due to the structural heterogeneity of starting backbone structures.  Furthermore, the 
modification of the backbone structure could determine the preference for the subsequent 
enzymatic modifications, and consequently regulate the synthesis of the polysaccharide 
with specific saccharide sequences (Esko 2002).  Availability of backbone structures 
with defined size and N-sulfation serves as an essential step towards the de novo 
synthesis of HS and a critical reagent to delineate the biosynthetic mechanism of HS. 
 
Section 2. Preparation of the glucuronyl transferases 
 
The biosynthesis of HS backbone is a repeating process of the alternating addition of 
GlcNAc and GlcA monosaccharide units (figure 9) to the growing polysaccharide chain 
by two glycosyltransferases.  With the glucosaminyl (GlcNAc) transferase KfiA 
available in large quantities, the next prerequisite for the in vitro synthesis of HS 
backbone is the glucuronyl (GlcA) transferase. 
 
1. KfiA/KfiC complex 
KfiC was previously identified as carrying the GlcA transferase activity in the elongation 
of E. coli K5 polysaccharide in a cell-based assay (Griffiths 1998).  The GlcA 
transferase activity of the recombinant KfiC was tested by a procedure modified from the 
previous report (Griffiths 1998).  Briefly, [3H]-labeled heptasaccharide was first 
prepared by adding a GlcN[3H]Ac residue to the nonreducing end of hexasaccharide 
through a KfiA reaction.  The resultant [3H]heptasaccharide was used as the acceptor 
substrate and the unlabeled UDP-GlcA was used as the donor substrate in the enzymatic 
assay described in figure 25A.  Purified proteins were incubated with acceptors and 
donors under the standard assay conditions.   The GlcA transferase activity was 
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measured by the resultant [3H]-labeled heptasaccharide on RPIP-HPLC (figure 25B). 
To our surprise, the purified KfiC did not show any detectable GlcA transferase 
activity (dotted line, figure 25B).  We, therefore, coexpressed full-length KfiA and KfiC 
in E. coli BL21 star cells and found that glucuronyl transferase activity was readily 
detectable in this enzyme complex (dashed line, figure 25B).  It is noteworthy that 
mixing KfiA and KfiC in vitro did not restore this activity, suggesting that the active form 
of KfiA/KfiC complex is established immediately after their biosynthesis.  Another 
possibility is that KfiA helps KfiC correctly fold into its active forms and that KfiC is still 
the real GlcA transferase.  However, our method cannot distinguish which possible 
scenario is correct. 
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 A 
 
B 
[3H]heptasaccharide 
[3H]octasaccharide 
 
Figure 25. GlcA transferase assay on KfiC and KfiA/KfiC 
 
A. The enzymatic assay used [3H]heptasaccharide as the acceptor and UDP-GlcA as the donor. 
The [3H]acetyl group is labeled with a red star. 
 
B. The resultant [3H]octasaccharide was resolved on RPIP-HPLC. 
Solid line: without any enzyme; dotted line: with KfiC; dashed line: with KfiA/KfiC complex. 
The starting [3H]heptasaccharide was eluted around 28 min and the resultant [3H]octasaccharide 
was eluted around 36 min. 
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The reactivity of KfiA/KfiC complex towards acceptor size is also critical for the de 
novo synthesis of HS backbones.  Although KfiA/KfiC is the only enzyme currently 
identified as carrying the GlcA transferase activity in E. coli K5, we failed in using this 
enzyme complex to work on trisaccharide with a GlcNAc residue at the non-reducing end.  
This suggests KfiA/KfiC may be only active on longer oligosaccharides or the growing 
K5 polysaccharide.  Other factors responsible for the GlcA activity in the initiation stage 
of the biosynthesis of K5 polysaccharide in E. coli cannot be ruled out. 
 
2. PmHS2 
PmHS1 and PmHS2 are the two bifunctional glycosyltransferases in P. multocida with 
both GlcNAc and GlcA transferase activities (DeAngelis 2002; DeAngelis 2004).  The 
full length PmHS2 gene was cloned from P. multocida type D genomic DNA and 
expressed in a format of 6×histidine tagged protein as described in “Materials and 
Methods”.  Recombinant PmHS2 was purified by affinity chromatography using a 
nickel column.  The purified PmHS2 predominantly migrated as one major band at ~73 
KDa on a 10% SDS-PAGE (figure 26), which is very close to the calculated molecular 
weight of PmHS2 (75 KDa).  We estimated that the purity of PmHS2 was greater than 
90%.  Approximately 15 mg of purified PmHS2 was obtained from 1 liter of bacterial 
culture. 
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Figure 26. SDS-PAGE of the purified PmHS2 
 
Affinity chromatography purified PmHS2 protein was resolved on precasted 10% SDS-PAGE.  
The gel was stained with coomassie blue.  Migration positions of molecular markers (from 
BioRad) are indicated.  The apparent mass was approximately 73 KDa. The predicted molecular 
mass of PmHS2 is 75 KDa. 
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The GlcA transferase activity of PmHS2 was tested in a reaction with trisaccharide 
(GlcNAc-GlcA-anManR) as acceptor substrates and UDP-[14C]GlcA as donor substrates 
as described in “Materials and Methods”.  The reaction mixture was loaded onto a 
Bio-Gel P10 column and the resultant [14C]-labeled tetrasaccharide was identified based 
on its molecular size and by comparing its elution position/time (P10 fraction number 66) 
with those of [3H]-labeled trisaccharide and [3H]-labeled pentasaccharide (figure 27).  
The elution positions of the [3H]-labeled trisaccharide (P10 fraction number 68) and 
pentasaccharide (P10 fraction number 61) prepared from radioactive KfiA reactions had 
been previously recorded as the standards.  A negative control reaction was also carried 
out unders standard conditions except for lacking the trisaccharide acceptor.  The results 
support that PmHS2 is active when a trisaccharide is used as its substrate. 
It is worthwhile noting that some of the UDP-[14C]GlcA degraded into [14C]GlcA 
even in the enzymatic assay with trisaccharide included (figure 27, fraction number 79) in 
the reaction catalyzed by PmHS2, raising the question of the catalytic efficiency of 
PmHS2 in the reaction of single sugar (GlcA) addition.  With this concern in mind, we 
found that PmHS2 can use oligosaccharides of various sizes as its acceptor (as short as a 
trisaccharide which could not be recognized by the complex of KfiA/KfiC).  This 
suggests that PmHS2 is indispensable in the de novo synthesis of HS backbones.  My 
work, therefore, has focused on using PmHS2 to synthesize the backbone of HS. 
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[14C]tetrasaccharide [14C]GlcA 
 
Figure 27. PmHS2 enzymatic assay on a Bio-Gel P10 column 
 
PmHS2-synthesized [14C]tetrasaccharide ([14C]GlcA-GlcNAc-GlcA-anManR) is shown in solid 
line and was eluted around fraction number 66 which is between the elution positions of 
trisaccharide (fraction number 68) and pentasaccharide (fraction number 61). 
The dotted line shows the product from the negative control reaction where no trisaccharide 
acceptor was included. 
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Section 3. Synthesis and test of UDP-N-trifluoroacetylglucosamine (UDP-GlcNCOCF3) 
 
The purpose of my research is to position the N-sulfated glucosamine (GlcNS) units in 
the backbone of HS.  It appears that using UDP-GlcNS as a donor is a direct approach.  
However, direct transfer of GlcNS is excluded at this point due to the unavailability of 
UDP-GlcNS.  To this end, we prepared UDP-GlcNAc derivatives, including 
UDP-glucosamine (UDP-GlcN) and UDP-N-trifluoroacetylglucosamine 
(UDP-GlcNCOCF3) as potential alternative donor substrates for KfiA reaction.  
Although the direct transfer of GlcN was not successful, we found that KfiA can 
recognize UDP-GlcNCOCF3 and transfer GlcNCOCF3 to oligosaccharide acceptors.  In 
this experiment, [3H]-labeled hexasaccharide was incubated with KfiA in the presence of 
UDP-GlcNCOCF3.  The resultant GlcNCOCF3-[3H]hexasaccharide was resolved by 
polyamine anion exchange-HPLC (PAMN-HPLC) (figure 28).  This finding is 
consistent with a previous study where UDP-GlcNCOCF3 was used as an unnatural donor 
of the “core 2” GlcNAc transferase (Sala 1998).  In the same study, the N-trifluoroacetyl 
groups were selectively removed from the sugar chain in a mild base condition without 
affecting the N-acetyl groups, providing a potential strategy to control the GlcNS 
positions on the backbone of HS.  Furthermore, compared with the N-acetyl groups, the 
N-trifluoroacetyl groups were more susceptible to the deacetylation treatment.  
Therefore, using UDP-GlcNCOCF3 is advantageous when we plan to prepare the 
completely N-unsubstituted HS backbones. 
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[3H]hexasaccharide 
GlcNCOCF3-[3H]hexasaccharide 
 
Figure 28. KfiA reaction using UDP-GlcNCOCF3.
 
The resultant GlcNCOCF3-[3H]hexasaccharide (eluted around 28 min) was shifted left to the 
starting [3H]hexasaccharide (eluted around 32 min) on PAMN-HPLC. 
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We further demonstrated that KfiA/KfiC complex indeed couples a GlcA to the 
GlcNCOCF3 end of oligosaccharide with high efficiency.  Here we prepared a 
heptasaccharide that contains a GlcNCOCF3 at the nonreducing end by incubating a 
hexasaccharide with UDP-GlcNCOCF3 in the presence of KfiA.  Further extension of 
GlcNCOCF3-hexasaccharide was achieved by incubating UDP-[14C]GlcA and 
GlcNCOCF3-hexasaccharide in the presence of KfiA/KfiC complex.  PAMN-HPLC 
profiles showed a ~90% yield of [14C]GlcA-GlcNCOCF3-hexasaccharide (a [14C]-labeled 
octasaccharide eluted around 33 min, figure 29).  It should be noted that PmHS2 can 
also transfer GlcA to the oligosaccharide acceptors that contain the GlcNCOCF3 residue 
at the nonreducing end as described below in Section 4. 
 
UDP-[14C]GlcA 
[14C]GlcA-GlcNCOCF3-hexasaccharide 
Figure 29. The complex of KfiA/KfiC transfers GlcA residue to GlcNCOCF3. 
Solid line: reaction without enzyme; Dotted line: reaction with KfiA/KfiC. 
UDP-[14C]GlcA was eluted around 47 min and the resultant [14C]-labeled octasaccharide was 
eluted around 33 min. 
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As UDP-GlcNCOCF3 is not commercially available, we developed a 
chemoenzymatic approach to synthesize this compound using 
N-acetylglucosamine-1-phosphate uridyltransferase (GlmU), in a similar way to that 
previously described in the synthesis of UDP-GlcN[3H]Ac (Leiting 1998) (figure 30). 
This two-step reaction uses GlcN-1-phosphate as the starting material.  
GlcN-1-phosphate first reacts with CF3CO-SC2H5 and yields GlcNCOCF3-1-phosphate, 
which is followed by the GlmU-catalyzed attachment of UDP to the C1 position on the 
GlcNCOCF3 sugar.  We obtained milligram-scale UDP-GlcNCOCF3 with this approach 
as described in “Materials and Methods”.  In addition, the Linhardt group at Rensselaer 
Polytechnic Institute (RPI) used a chemical approach and synthesized 100 mg quantities 
of UDP-GlcNCOCF3 for us as a large scale source of this UDP-sugar.   
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Figure 30. Chemoenzymatic synthesis of UDP-GlcNCOCF3 (courtesy of Renpeng Liu) 
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Section 4. De novo synthesis and purification of heparosan 
 
1. Preparation of the starting material-disaccharide 
In order to control the N-sulfation and, therefore, the O-sulfation pattern of HS, it is 
necessary to synthesize the HS backbone from disaccharide.  The starting disaccharide, 
GlcA-anManR, was prepared by the complete N-deacetylation and depolymerization of 
K5 polysaccharide (figure 31A).  The [14C]-labeled K5 polysaccharide was first subject 
to complete degradation and the resultant [14C]disaccharide was loaded onto a Bio-Gel 
P10 column as a standard (figure 31B).  The nonradioactive disaccharide was, thereafter, 
prepared in a large scale and purified with a P10 column by blindly collecting all the P10 
fractions between 70 and 78 that was decided by the elution position of the 
[14C]disaccharide standard.  Approximately 100 mg of K5 polysaccharide was degraded 
to disaccharide using nitrous acid for my study. 
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Figure 31. Preparation of disaccharide  
A. Complete degradation of K5 polysaccharide into disaccharide 
The incubation time of K5 polysaccharide with 2 M NaOH is critical for the extent of 
N-deacetylation and it should be more than 3 hours to reach completion. 
B. The [14C]disaccharide used as a standard on a Bio-Gel P10 column 
Most of the [14C]-labeled K5 polysaccharide was completely depolymerized into 
[14C]disaccharide (GlcA-anManR) which was eluted around fraction number 74 (ranging from 
number 70 to number 78) on the P10 column (15 drops/fraction).  There was a minor peak at 
fraction number 64 believed to be [14C]tetrasaccharide (GlcA-GlcNAc-GlcA-anManR) coming 
from the partial degradation of K5 polysaccharide. 
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2. Synthesis of trisaccharide 
Trisaccharide, GlcNAc-GlcA-anManR, was synthesized with disaccharide (GlcA-anManR) 
as acceptor and UDP-GlcNAc as donor in a KfiA reaction (figure 32A).  Similar to the 
strategy we used to purify disaccharide, the [3H]trisaccharide was prepared from a 
radioactive KfiA reaction using unlabeled disaccharide and UDP-GlcN[3H]Ac.  The 
product was loaded onto a Bio-Gel P10 column to locate the elution position of a 
trisaccharide (figure 32B).  A nonradioactive trisaccharide was then prepared by KfiA in 
the presence of unlabeled UDP-GlcNAc. 
Complete removal of UDP-GlcNAc from the reaction product is essential for the 
subsequent PmHS2-catalyzed synthesis of tetrasaccharide.  If UDP-GlcNAc is present 
with UDP-GlcA, PmHS2, a bifunctional enzyme with both GlcNAc and GlcA transferase 
activities, is able to extend the trisaccharide to polysaccharide, which will reduce the 
yield of tetrasaccharide significantly.  However, trisaccharide and UDP-GlcNAc cannot 
be resolved very well on P10 column.  To overcome this problem, a limited amount of 
UDP-GlcNAc was incubated with excess disaccharide acceptor to exhaust UDP-GlcNAc 
under the standard conditions.  The resultant trisaccharide was purified with P10 column.  
Whether the trisaccharide was produced was determined by the level of the transfer of 
[14C]GlcA using PmHS2. 
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Figure 32. Synthesis of trisaccharide 
 
A. KfiA transfers the GlcNAc residue to disaccharide 
 
B. The elution profile of the [3H]trisaccharide standard on a Bio-Gel P10 column 
[3H]trisaccharide standard was prepared from a KfiA reaction containing UDP-GlcN[3H]Ac and  
it was eluted from fraction number 65 to 71 (peaked at number 68) on the P10 column (15 
drops/fraction).   
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3. Synthesis of unnatural oligosaccharide backbones 
As mentioned previously, UDP-GlcNCOCF3 was used by KfiA as well as its natural 
donor substrate UDP-GlcNAc.  Therefore, the unnatural HS backbones with repeating 
-GlcA-GlcNCOCF3- disaccharide unit can also be synthesized with KfiA and PmHS2 as 
illustrated in figure 33.  Then we focused our attention on the synthesis of the unnatural 
backbone with GlcNCOCF3 other than the natural one containing GlcNAc, in order to 
control the N-sulfation of HS oligosaccharides. 
 
 
Figure 33. Synthesis of HS unnatural backbones with various size 
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Synthesis of unnatural trisaccharide (GlcNCOCF3-GlcA-anManR) 
In the first step, we started with the disaccharide (GlcA-anManR) (4.5 μmole, 1.52 mg) as 
the acceptor and UDP-GlcNCOCF3 (3.9 μmole, 2.58 mg) as the unnatural donor substrate 
in the presence of KfiA as described in “Materials and Methods” (figure 34A).  The 
resultant unnatural trisaccharide (GlcNCOCF3-GlcA-anManR) was purified with a 
Bio-Gel P10 column in a similar fashion as we prepared the natural trisaccharide 
(GlcNAc-GlcA-anManR).  The fractions from P10 column corresponding to the 
synthesized unnatural trisaccharide were blindly recovered according to the elution 
position of the [3H]trisaccharide standard (GlcN[3H]Ac-GlcA-anManR).  The purified 
unnatural trisaccharide (GlcNCOCF3-GlcA-anManR) was dissolved in ddH2O and 
subjected to a test to check its quantity and purity.  This test used PmHS2 and excess 
UDP-[14C]GlcA with known concentration (100 µM) and specific activity (200 
mCi/mMole).  The resultant tetrasaccharide ([14C]GlcA-GlcNCOCF3-GlcA-anManR) 
was analyzed on the P10 column (figure 34B) and its quantity was calculated based on 
the specific activity of UDP-[14C]GlcA.  There was no other oligosaccharide peak 
besides the expected [14C]tetrasaccharide, indicating that the synthesized trisaccharide 
was pure.  There was a notable [14C]-labeled unknown species that eluted very late 
(around fraction number 77) on the P10 column.  Its molecular weight was close to 
monosaccharide ([14C]GlcA, figure 34B), which is consistent with our speculation on the 
degradation of UDP-[14C]GlcA into [14C]GlcA by PmHS2 in the reaction.  The amount 
of the synthesized trisaccharide was 2.87 μmole (1.71 mg).  The yield of the synthesis of 
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trisaccharide (GlcNCOCF3-GlcA-anManR) was about 73 % based on the amount of 
UDP-GlcNCOCF3 (3.9 μmole, 2.58 mg) used in the reaction.    
 
A 
 
B 
[14C]tetrasaccharide 
[14C]GlcA 
Figure 34. Synthesis of unnatural trisaccharide 
A. KfiA transfers the GlcNCOCF3 residue to disaccharide. 
The resultant trisaccharide was tested in a subsequent radioactive reaction catalyzed by PmHS2. 
B. Test on the quality and quantity the synthesized unnatural trisaccharide 
The tested trisaccharide and UDP-[14C]GlcA was incubated with PmHS2.  The resultant 
[14C]tetrasaccharide was eluted around fraction number 65 on the P10 column.  The second peak 
(fraction number 79) is believed to be [14C]GlcA degraded from UDP-[14C]GlcA. 
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Synthesis of unnatural tetrasaccharide (GlcA-GlcNCOCF3-GlcA-anManR) 
The synthesized trisaccharide was further elongated to an unnatural tetrasaccharide 
(GlcA-GlcNCOCF3-GlcA-anManR) in a subsequent reaction catalyzed by PmHS2 as 
described in “Materials and Methods” (figure 35A).  Because the elution positions of 
trisaccharide and the resultant tetrasaccharide were too close to each other, it was difficult 
to separate tetrasaccharide from the unreacted trisaccharide.  To overcome this problem, 
a limited amount of trisaccharide was incubated with excess UDP-GlcNCOCF3 under 
standard conditions.  Trisaccharide was exhausted and the unreacted UDP-GlcNCOCF3 
was completely removed from the resultant tetrasaccharide with a P10 column. 
In details, as shown in figure 34, we knew where the radio-labeled tetrasaccharide 
([14C]GlcA-GlcNCOCF3-GlcA-anManR) eluted and use its elution position (fraction 
number 65 on P10 column) as the standard to blindly recover the purified unnatural 
tetrasaccharide (GlcA-GlcNCOCF3-GlcA-anManR).  Similarly, the purity and quantity 
of the purified GlcA-GlcNCOCF3-GlcA-anManR was subject to a KfiA-catalyzed test 
with the donor substrate UDP-GlcN[3H]Ac (407 µM, 172 mCi/mMole) in excess.  The 
analysis with P10 column showed that the reaction product contained only 
[3H]pentasaccharide (GlcN[3H]Ac-GlcA-GlcNCOCF3-GlcA-anManR) and the unreacted 
UDP-GlcN[3H]Ac without any other sugar of different size.  This suggested that the 
tested tetrasaccharide was pure (figure 35B).  The quantity of the synthesized 
tetrasaccharide was estimated to be 1.79 μmole (1.38 mg) based on the specific activity of 
UDP-GlcN[3H]Ac.  The yield of the KfiA-catalyzed elongation reaction (from 
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trisaccharide to tetrasaccharide) was around 62 %. 
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Figure 35. Synthesis of unnatural tetrasaccharide 
 
A. PmHS2 transfers the GlcA residue to trisaccharide 
The resultant tetrasaccharide was tested in a subsequent radioactive reaction catalyzed by KfiA. 
B. Test on the quality and quantity the synthesized unnatural tetrasaccharide 
[3H]pentasaccharide was produced from a KfiA-catalyzed test reaction containing 
UDP-GlcN[3H]Ac and was eluted around fraction number 58 to 64 (peaked at number 61) on the 
P10 column (15 drops/fraction).  The second peak (around number 72) is believed to be 
unreacted UDP-GlcN[3H]Ac. 
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Section 5. Synthesis of longer unnatural oligosaccharides 
 
The alternate KfiA and PmHS2 elongation reactions were repeated stepwise.  In each 
step, the quality and quantity of the resultant products were closely controlled in an 
approach described above, until the sugar chain reached the desired size.  In summary, 
we prepared the unnatural HS backbones at 100 μg to milligram scales (table 6).  All of 
these oligosaccharides contain GlcNCOCF3 only without GlcNAc residues.  The 
sequence of the synthesized tetrasaccharide, hexasaccharide and octasaccharide were 
confirmed by mass spectrometry by Linhardt’s group at the Rensselaer Polytechnic 
Institute (RPI).  As an example, 1 μg of the unnatural octasaccharide, 
(GlcA-GlcNCOCF3)3-GlcA-anManR, was examined by LC-MS and MS/MS as described 
in “Materials and Methods”.  The formula weight of the octasaccharide was 1640.1 
(C54H74O44N3F9) which is very close to the molecular weight (1640.0) calculated based 
on its MS spectrum ([M-2H]2- and [M+Na-2H]2-, figure 36A).  The subsequent MS/MS 
spectrum further confirmed its structure by identifying various fragmentations (figure 
36B). 
In summary, our results demonstrated that it is feasible to synthesize HS backbones 
with the two bacterial glycosyltransferases (KfiA and PmHS2).  These results also 
support our hypotheses that UDP-GlcCOCF3 can be employed to build unnatural HS 
backbones and that the size of HS oligosaccharides can be precisely controlled by 
regulating the access of KfiA, PmHS2 and the two UDP-sugar donor substrates. 
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Molecular weight (Da) 
Structure of oligosaccharides 
Number 
of sugar 
residues
Amount 
(µg) Calculated Determineda
GlcNCOCF3-GlcA-anManR 3 1710 -- 
Not 
determined 
GlcA-GlcNCOCF3-GlcA-anManR 4 1380 -- 
Not 
determined 
GlcA-GlcNCOCF3-GlcA-anMannoseb 4 160 771 771 
GlcA-GlcN-GlcA-GlcN-GlcA-anManRc 6 150 1013 1014 
(GlcA-GlcNCOCF3)3-GlcA-anManR 8 280 1639 1640 
(GlcA-GlcNCOCF3)4-GlcA-anManR 10 250 -- 
Not 
determined 
(GlcNCOCF3-GlcA)5-anManR 11 400 -- 
Not 
determined 
 
Table 6. List of the synthesized oligosaccharides 
 
a. Molecular weight was determined by LC-MS and MS/MS in Linhardt’s group at RPI. 
 
b. The reducing end of this tetrasaccharide contains anhydromannose, instead of 
anhydromannitol. 
 
c. The hexasaccharide was completely N-deacetylated (N-unsubstituted). 
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Figure 36. MS and MS/MS performed on 1 μg of octasaccharide 
 
A. MS spectrum of octasaccharide 
B. MS/MS spectrum and scheme of fragmentation of octasaccharide 
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Chapter V. Modifications of heparan sulfate backbones 
 
Section 1. Introduction 
A set of HS modification enzymes, including N-sulfotransferase (NST), C5-epimerase 
(C5-epi), 2-O-sulfotransferase (2OST), 6-O-sulfotransferase isoforms 1 and 3 (6OST1 
and 6OST3), and 3-O-sulfotransferase isoform 1 (3OST1) have been cloned and 
expressed in large quantities in our laboratory.  The availabilities of these biosynthetic 
enzymes and the HS backbones allow us to prepare the HS oligosaccharides with desired 
sizes and sulfation patterns.  Directed by the knowledge of the biosynthesis of HS and 
the structures of several known anticoagulant HS oligosaccharides (Vuillemenot 1999; 
Chen 2007), we synthesized HS oligosaccharides with more defined structures and with 
antithrombin (AT)-binding activity enzymatically.   
Section 2. N-deacetylation and N-sulfation of heparan sulfate backbones 
In the biosynthesis of HS, the downstream epimerization and various O-sulfations 
preferentially occur at the disaccharide units having N-sulfations (Jacobsson 1984). As 
NST only reacts at the glucosamine residue with a free amine group at the N position, 
N-deacetylation is, thus, a decisive step in the modifications of HS backbones.  
Compared with the natural HS backbones with GlcNAc residues, the unnatural 
backbones we prepared contain GlcNCOCF3 residues.  The incorporated GlcNCOCF3 
residues can be deemed as the protected forms of GlcN, because the selective removal of 
the N-trifluoroacetyl group can be achieved under mild conditions while the N-acetyl 
group will be retained.  The selective N-deacetylation is, therefore, feasible by placing 
GlcNCOCF3 and GlcNAc at desired places on the sugar chain.  The complete 
N-deacetylation of HS backbones containing GlcNCOCF3 is also less demanding than 
those with natural GlcNAc residues. 
 
1. Complete N-deacetylation/N-sulfation of [3H]-labeled heptasaccharide 
A small amount of [3H]-heptasaccharide (figure 37D, compound a) was first used to test 
the efficiency of our approach for complete N-deacetylation/N-sulfation as described in 
figure 37D.  The N-unsubstituted [3H]-heptasaccharide (compound b), and the 2-hour 
and overnight NST reactions were analyzed by RPIP-HPLC (figure 37, panel A, B, C).  
Compared with compound b, compounds c and d were eluted later on RPIP-HPLC.  
Since there are only two susceptible N-sulfation sites for compound b, we believe that 
they were partially and completely N-sulfated [3H]-heptasaccharides, respectively.  
Compound c (figure 37B, 27 min) represents a monosulfated heptasaccharide and 
compound d (figure 37B and C, 35min) represents a disulfated heptasaccharide.  Based 
on this analysis, we estimated that the purity of the fully N-sulfated [3H]-heptasaccharide 
(compound d) in the overnight NST reaction was greater than 90%.  This experiment 
also demonstrated that when the heptasaccharide was treated with triethylamine for 
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N-deacetylation, only its two N-trifluoroacetyl groups were susceptible and the 
[3H]-labeled N-acetyl group was intact on the backbone.  The result proves that the 
selective N-deacetylation can be achieved with triethylamine. 
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Figure 37. Complete N-deacetylation/N-sulfation of [3H]-labeled heptasaccharide 
A. The N-unsubstituted [3H]-heptasaccharide analyzed on RPIP-HPLC 
B. The RPIP-HPLC profile of the products from 2-hour NST reaction 
C. The RPIP-HPLC profile of the product from overnight NST reaction 
D. Synthetic scheme of N-deacetylation/N-sulfation 
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To prepare NS-[3H]-heptasaccharide in a larger scale for further structural analysis, 
the hexasaccharide backbone (figure 38A) was first prepared with alternate KfiA and 
PmHS2 reactions and purified with a Bio-Gel P10 column as described in Chapter V.  
The complete N-deacetylation of its GlcNCOCF3 residues with triethylamine in aqueous 
methanol yielded an N-unsubstituted hexasaccharide which was confirmed by mass 
spectrometry (table 6).  An additional GlcN[3H]Ac monosaccharide was then added to 
the non-reducing end of the hexasaccharide as a radioactive label in a KfiA reaction using 
UDP-GlcN[3H]Ac.  The product was purified by a P10 column.  This was followed by 
an NST reaction coupled with PAPS regeneration system leading to the N-sulfation of 
[3H]-labeled heptasaccharide, which was purified by RPIP-HPLC (figure 38B).  The 
majority of NS-[3H]heptasaccharide bound with the RPIP column tightly by forming a 
hydrophobic ion paired complex with tetrabutylammonium (TBA) and was eluted at 
around 31 min.  The earlier and smaller peak (eluted at around 7 min) represented the 
unbound product since when the load of NS-[3H]heptasaccharide decreased, this peak 
disappeared.   
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Figure 38. Preparation of N-deacetylated/N-sulfated [3H]-heptasaccharide 
 
A. synthetic route 
B. purification of N-sulfated [3H]heptasaccharide 
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To examine the extent of N-deacetylation and N-sulfation, both high pH and low pH 
nitrous acid degradation tests were performed on [3H]-labeled heptasaccharide before and 
after the NST reaction (figure 39C).  At high pH (pH 4.5-5.5), nitrous acid only cleaves 
the oligosaccharide at the N-deacetylated glucosamine residues with free amine groups.  
In contrast, at low pH (pH 1.5), nitrous acid predominantly reacts at the N-sulfated 
glucosamine residues.  The products from the four tests were resolved with a Bio-Gel 
P10 column based on their molecular size (figure 39A, 39B).  Our results demonstrated 
that before the NST reaction, the [3H]-labeled heptasaccharide was resistant to low pH 
degradation and remained intact as a heptasaccharide, while it was sensitive to high pH 
degradation and was completely degraded to a [3H]-labeled trisaccharide without any 
partial degradation (figure 39A).  This suggests that after N-deacetylation, the 
N-trifluoroacetyl groups were completely removed from the HS backbone.  In contrast, 
after the NST reaction, the [3H]-labeled heptasaccharide became resistant to high pH 
degradation and could be completely degraded into [3H]-labeled trisaccharide by low pH 
degradation (figure 39B), indicating that N-sulfation was complete and there was no free 
amine groups left on the glucosamine residues of the HS backbone.  
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Figure 39. Nitrous acid degradation of [3H]heptasaccharide 
A. low pH (dashed line) and high pH (solid line) nitrous acid degradation of N-deacetylated 
[3H]heptasaccharide 
B. low pH (dashed line) and high pH (solid line) nitrous acid degradation of N-sulfated 
[3H]heptasaccharide 
C. N-deacetylated [3H]heptasaccharide is susceptible to high pH degradation and N-sulfated 
[3H]heptasaccharide is susceptible to low pH degradation.  The resultant [3H]trisaccharides were 
detected as shown in panel A and B.  The low pH treatment of N-deacetylated 
[3H]heptasaccharide and high pH treatment of N-sulfated [3H]heptasaccharide did not cause any 
degradation and thus are not drawn.  
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2. Complete N-deacetylation/N-sulfation of [3H]-labeled undecasaccharide 
As there were only two GlcNCOCF3 residues in the [3H]-labeled heptasaccharide to be 
N-deacetylated and sulfated, we further used [3H]-labeled undecasaccharide, to test if our 
approach was still effective for longer HS backbones.   
The decasaccharide backbone (figure 40A) was N-deacetylated by triethylamine.  
GlcN[3H]Ac was again attached to the non-reducing end of the decasaccharide as a 
radioactive label, followed by purification with a Bio-Gel P10 column and a subsequent 
NST reaction.  The resultant N-sulfated and [3H]-labeled undecasaccharide was purified 
by PAMN-HPLC (figure 40B).  The major radioactive population corresponding to the 
elution time 51-54 min on PAMN-HPLC was pooled and saved for further modification. 
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Figure 40. Preparation of N-deacetylated/N-sulfated [3H]-undecasaccharide 
A. Synthetic route 
B. Purification of the N-sulfated [3H]undecasaccharide (51-54min) 
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The extent of N-sulfation on the resultant undecasaccharide was examined by high pH 
and low pH nitrous acid degradation before and after the NST reaction (figure 41A, B).  
Similar to previous observations, the unsulfated undecasaccharide was intact when 
treated with nitrous acid at low pH, but was completely degraded to a [3H]-labeled 
trisaccharide at high pH (figure 41A).  On the contrary, the N-sulfated undecasaccharide 
became completely sensitive to low pH nitrous acid degradation and resistant to high pH 
nitrous acid depolymerization (figure 41B).  The results indicate that the synthesized 
NS-[3H]undecasaccharide was indeed fully N-deacetylated/N-sulfated.  Meanwhile, a 
partially N-sulfated dodecasaccharide with a [14C]GlcA residue at its nonreducing end 
was also treated with nitrous acid at low pH.  The degradation yielded both 
[14C]tetrasaccharide and [14C]disaccharide (figure 41C).  The result was consistent with 
our expected outcome.  Some of the glucosamine residues on this [14C]dodecasaccharide 
do not have N-sulfation.  Therefore, some of the [14C]dodecasaccharide are resistant to 
the complete degradation by nitrous acid at low pH.  The result also confirms that 
nitrous acid degradation is able to probe the incompletion of N-deacetylation/N-sulfation. 
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Figure 41. Nitrous acid degradation of [3H]undecasaccharide 
A. low pH (dashed line) and high pH (solid line) nitrous acid degradation of N-deacetylated 
[3H]undecasaccharide 
B. low pH (dashed line) and high pH (solid line) nitrous acid degradation of N-sulfated 
[3H]undecasaccharide 
C. low pH nitrous acid degradation of partially N-sulfated [14C]dodecasaccharide 
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Section 3. Synthesis of heparan sulfate octasaccharide with AT-binding affinity 
 
The Arixtra pentasaccharide (figure 5) is an AT-binding structure which works as a 
template for our synthesis.  Using HS biosynthetic enzymes and the appropriately 
N-sulfated HS backbone, we synthesized HS octasaccharide containing this AT-binding 
domain by a route described in figure 42. 
 
 
 
Figure 42. Synthetic route to the HS octasaccharide with AT-binding affinity 
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The synthesis started with an unnatural hexasaccharide containing GlcNCOCF3 
residues, which was followed by the complete N-deacetylation by triethylamine and 
complete N-sulfation by NST (figure 42).  The reaction yielded a completely N-sulfated 
hexasaccharide without radioactivity which was purified with a Bio-Gel P10 column.  
Its elution time/position on P10 column was already calibrated with an 
N[35S]-hexasaccharide standard prepared from an NST reaction using PAP[35S] (figure 
43).  PAP[35S] was eluted very late and far away from N[35S]-hexasaccharide, 
suggesting that P10 column has sufficient capability to purify NS-hexasaccharide from 
other reaction reagent which was predominantly unreacted PAPS. 
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Figure 43. Elution time/position of N[35S]-hexasaccharide on P10 column 
 
N[35S]-hexasaccharide (eluted from fraction number 56 to 62) was used as a standard to calibrate 
where NS-hexasaccharide is eluted on P10 column.  Unreacted PAP[35S] was eluted around 
fraction number 73.   
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Considering the HS biosynthetic enzymes may need flanking region to efficiently 
react with the pentasaccharide domain, we added two more sugar residues to the 
non-reducing end of the N-sulfated hexasaccharide.  These two extension reactions were 
catalyzed by KfiA and PmHS2, and the respective products were blindly purified with a 
P10 column based on their molecular size.  The synthesized N-sulfated octasaccharide 
(figure 42, compound e) was subject to further modifications (epimerization, 
2-O-sulfation, 6-O-sulfation, and 3-O-sulfation) in a one-pot reaction using [35S]-labeled 
PAPS.  To test if the resultant octasaccharide (figure 52, compound f) binds to AT, an 
assay was carried out with concanavalin A (ConA)-sepharose as described in “Materials 
and Methods”.  The synthesized octasaccharide had a reasonable binding affinity to AT.  
In contrast, the octasaccharide lost its AT-binding capability in the negative control even 
if only the last-step modification of 3-O-sulfation was neglected (table 7). 
 
Enzymatic modifications 
Starting substrate 
C5-epi 2OST 6OST1 6OST3 3OST1 
AT-binding 
Octasaccharide 
(cpm) 
Yes Yes Yes Yes 26220 NS-octasaccharide 
(compound e) Yes Yes Yes No 350 
 
Table 7. The synthesized HS octasaccharide binds to AT in a ConA-based assay 
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Collectively, our data demonstrated that the synthesized HS backbones with 
GlcNCOCF3 residues can be fully N-deacetylated/N-sulfated in a chemoenzymatic 
approach.  In addition, the resultant N-sulfated oligosaccharides can be effectively 
modified by HS biosynthetic enzymes (C5-epi, 2OST, 6OSTs and 3OST1).  The 
modified final product binds to AT.  
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Chapter VI. Conclusion 
 
Widely distributed on the cell surface and in the extracellular matrix, HS plays important 
roles in various biological processes, including cell differentiation, signaling, 
inflammatory response, blood coagulation and pathogen invasion (Bishop 2007).  The 
significant medical potential of HS makes it an attractive target for pharmaceutical 
research.  Heparin, a specialized form of HS, has been a commonly used anticoagulant 
drug for decades and HS is also recently employed in treating cancers and inflammatory 
disorders (McLean 1916; Fuster 2005; Parish 2005).  However, as a natural product 
extracted from animal tissues, HS may lead to risky side effects due to its heterogeneous 
structure and potential contamination.  A recent medical accident was reported that 
heparin distributed by Baxter International was contaminated and has caused 81 deaths in 
the United States according to the report by The New York Times (The New York Times 
April 28, 2008).   
To improve the homogeneity of heparin-based drugs and their quality control, one of 
the major focuses in the field of carbohydrate research has been the development of 
synthetic substitute for heparin.  Chemical synthesis has been an important approach to 
make small molecules but remains inefficient in the synthesis of oligosaccharides larger 
than hexasaccharide.  Our group and others have begun to synthesize bioactive HS with 
a collection of its biosynthetic enzymes (Kuberan 2003; Chen 2005; Lindahl 2005; 
Muñoz 2006), although these approaches were at the polysaccharide level and the 
synthesized HS were still heterogeneous. 
Busse and Kusche-Gullberg used mammalian HS polymerases EXT1 and EXT1/2 to 
synthesize HS polysaccharide backbones in vitro (Busse 2003).  In my research a 
chemoenzymatic method has been developed first time to synthesize HS oligosaccharides 
with desired size and defined N-sulfation.  My approach exploits the two bacterial 
glycosyltransferases, KfiA (Hodson 2000) and PmHS2 (DeAngelis 2004), to build the HS 
backbones de novo using a K5 polysaccharide-derived disaccharide (GlcA-anManR) as 
the staring substrate.  The enzymatic assays in Chapter III and IV demonstrated that 
both KfiA and PmHS2 are active on small oligosaccharides (disaccharide and 
trisaccharide) and capable of initiating the polymerization of sugar chain.  The size of 
the synthesized oligosaccharides was precisely controlled in the stepwise elongation by 
KfiA and PmHS2.  In addition, long oligosaccharides larger than decasaccharide can 
also be easily synthesized with this method, providing a valuable alternative for chemical 
synthesis.  Besides KfiA and PmHS2, the recombinant KfiC also demonstrates a notable 
GlcA transferase activity when it was coexpressed with KfiA in E. coli and a 
heptasaccharide substrate was used in Chapter IV.  However, it cannot work on 
trisaccharide, suggesting that KfiC may only be responsible for the elongation of the 
initiated sugar chain in vivo.  
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Another advantage of the de novo synthesis is that it facilitates the substitution of the 
unnatural sugar residue for the natural one on the HS backbones.  Although KfiA can 
not directly incorporate GlcNS into the growing backbone, we found that KfiA can use 
UDP-GlcNCOCF3 as an unnatural donor in the GlcNAc transferase reaction as efficiently 
as UDP-GlcNAc.  In the de novo synthesis, the GlcNCOCF3 residue can be placed at 
any desired glucosamine position on HS backbones and is labile to N-deacetylation with 
the treatment of triethylamine.  The natural GlcNAc residue is, however, resistant to this 
treatment and remains intact.  Because NST only reacts with the N-unsubstituted 
glucosamine, the selective N-deacetylation results in the selective N-sulfation.  In this 
way, N-sulfation on the HS backbones can be precisely regulated.  The subsequent 
epimerization and O-sulfations dictated by N-sulfation may also be controlled as 
demonstrated by the AT-binding octasaccharide in Chapter V (figure 52, compound f). 
The specific function of HS relies on its particular sulfation patterns which results 
from the modifications catalyzed by various HS biosynthetic enzymes.  Unlike DNA 
and protein, the biosynthesis of HS is not a template-driven process.  A complete picture 
on the substrate specificities of HS modification enzymes has not been obtained due to 
the limited availability of structure-defined HS substrates.  The lack of this knowledge 
prevents the researchers from clarifying the regulating mechanisms of the biosynthesis of 
HS.  This dissertation proposed a feasible chemoenzymatic approach to synthesize 
oligosaccharide backbones with desired size and controlled N-sulfation.  These 
compounds may serve as potential substrates to study the substrate specificities of HS 
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biosynthetic enzymes, including C5-epi, 2-O, 6-O, and 3-O-sulfotransferases, at the 
oligosaccharide level.  This type of research will help us understand how the size of HS 
backbones and the distribution of its N-sulfations control the extent of downstream 
epimerization and O-sulfations.  This will ultimately help to answer how the specific HS 
structures are generated and regulated in vivo. 
The chemoenzymatic method developed in this dissertation can also be used to 
prepare an oligosaccharide library with various size and diverse N-sulfation patterns.  In 
a recent study, Chen and colleagues found that the size of the 3-O-sulfated HS 
oligosaccharides is critical for their anticoagulant characters (Chen 2007).  Therefore, 
such a library will be valuable to probe the structure-function relationship of bioactive HS.  
As an example, a target library containing pentasaccharides, hexasaccharides and 
heptasaccharides can be summarized in table 8.  
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Size Structure Number of NS 
GlcNAc-GlcA-GlcNAc-GlcA-anManR 0 
GlcNS-GlcA-GlcNAc-GlcA- anManR 1 
GlcNAc-GlcA-GlcNS-GlcA-anManR 1 
Pentasaccharide 
GlcNS-GlcA-GlcNS-GlcA-anManR 2 
GlcA-GlcNAc-GlcA-GlcNAc-GlcA-anManR 0 
GlcA-GlcNS-GlcA-GlcNAc-GlcA- anManR 1 
GlcA-GlcNAc-GlcA-GlcNS-GlcA-anManR 1 
Hexasaccharide 
GlcA-GlcNS-GlcA-GlcNS-GlcA-anManR 2 
GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-anManR 0 
GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-anManR 1 
GlcNAc-GlcA-GlcNS-GlcA-GlcNAc-GlcA-anManR 1 
GlcNAc-GlcA-GlcNAc-GlcA-GlcNS-GlcA-anManR 1 
GlcNS-GlcA-GlcNS-GlcA-GlcNAc-GlcA-anManR 2 
GlcNS-GlcA-GlcNAc-GlcA-GlcNS-GlcA-anManR 2 
GlcNAc-GlcA-GlcNS-GlcA-GlcNS-GlcA-anManR 2 
Heptasaccharide 
GlcNS-GlcA-GlcNS-GlcA-GlcNS-GlcA-anManR 3 
 
Table 8. The list of the oligosaccharides included in a target library 
The N-sulfated glucosamine (GlcNS) residues are shown in red. 
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Our approach yielded the structure-defined HS oligosaccharides at 100 µg level.  In 
future studies, the synthesis should be scaled up with larger quantities of acceptor and 
donor substrates.  In addition, a fluorous tagging strategy is being developed in our 
group to simplify the purification of the synthesized oligosaccharides (Zhang 2004).  We 
expect the yield of each elongation step may be improved with the aid of this phase-tag 
method.  More importantly, the reduced purification time with the fluorous tagging 
strategy makes it less demanding to prepare the oligosaccharide library mentioned in 
table 8.   
Besides the AT-binding octasaccharide, the chemoenzymatic method described in this 
dissertation may be used to synthesize other bioactive HS oligosaccharides as a general 
approach.  This exploratory study is the foundation for de novo synthesis of the 
structure-defined HS oligosaccharides with various biological functions, which may 
become novel therapeutic agents for cardiovascular diseases, cancers and inflammatory 
disorders.   
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